1. INTRODUCTION
===============

Lung cancer represents a major health burden in Canada. Approximately 23,300 new lung cancer cases and 19,900 deaths from lung cancer occurred in 2007, most of which were non-small-cell lung cancer ([nsclc]{.smallcaps})[@b1-co16-1-27]. Most of these patients either present with or develop metastatic disease at some point during their illness; potentially, they are candidates for systemic therapy approaches such as chemotherapy.

Until the late 1990s, therapeutic nihilism about the benefit of systemic chemotherapy in the treatment of advanced and metastatic [nsclc]{.smallcaps} was widespread. Publication of the Non-small Cell Lung Cancer Collaborative Group meta-analysis in 1995 established the association of first-line platinum-based chemotherapy with a modest improvement in survival for patients with metastatic disease[@b2-co16-1-27]. The introduction of newer drugs such as vinorelbine, gemcitabine, paclitaxel, and docetaxel have resulted in further small improvements, although most patients still experience disease progression within a short time, with a median time to progression ([ttp]{.smallcaps}) of approximately 4 months [@b3-co16-1-27]--[@b5-co16-1-27].

At the time of progression following platinum-based chemotherapy, many patients maintain a good performance status ([ps]{.smallcaps}) and may be candidates for further systemic therapy. Recent trials have established that second-line chemotherapy with docetaxel[@b6-co16-1-27]--[@b9-co16-1-27] improves survival and quality of life ([qol]{.smallcaps}) as compared with best supportive care ([bsc]{.smallcaps}) and that survival of patients treated with docetaxel or pemetrexed is similar[@b10-co16-1-27]. Guidelines for the management of [nsclc]{.smallcaps}, including those from Cancer Care Ontario's Program in Evidence-Based Care ([cco-pebc]{.smallcaps})[@b11-co16-1-27] now recommend either of those agents as second-line chemotherapy options[@b11-co16-1-27],[@b12-co16-1-27].

Despite these advancements in the treatment of [nsclc]{.smallcaps}, there is still a strong need for additional and better treatment options. Recently, a greater understanding of the molecular abnormalities associated with [nsclc]{.smallcaps} has led to evaluation of new therapeutic targets for [nsclc]{.smallcaps}. The epidermal growth factor receptor ([egfr]{.smallcaps}) is one target commonly overexpressed in [nsclc]{.smallcaps}[@b13-co16-1-27]--[@b15-co16-1-27]. Early-phase clinical trials showed that [egfr]{.smallcaps} tyrosine kinase inhibitors ([tkis]{.smallcaps}) such as erlotinib and gefitinib had antitumour activity, and this finding prompted their further evaluation in advanced [nsclc]{.smallcaps}[@b16-co16-1-27] These agents have been evaluated extensively in phase [ii]{.smallcaps} and [iii]{.smallcaps} trials over the last few years, confirming the promising activity seen in phase [i]{.smallcaps} trials, and the [tkis]{.smallcaps} have been incorporated into treatment algorithms for patients after progression on standard chemotherapy options[@b11-co16-1-27].

Because of a favourable toxicity profile of the [tkis]{.smallcaps}, many clinicians felt that it might be appropriate to expand their role in the treatment of advanced and metastatic [nsclc]{.smallcaps}. A need therefore exists to clarify the role of [egfr]{.smallcaps}-[tkis]{.smallcaps} in the treatment of [nsclc]{.smallcaps}. The present paper represents a consensus view of a representative sample of Canadian lung cancer medical oncologists on the role of [egfr]{.smallcaps}-[tkis]{.smallcaps} in the treatment of [nsclc]{.smallcaps} based on a systematic review of currently available evidence.

2. MATERIALS AND METHODS
========================

Medical oncologists specializing in thoracic oncology from five provinces across Canada were invited to participate in a consensus meeting. Six oncologists attended the consensus meeting, and three additional oncologists, plus one pathologist, provided input into the consensus process. Three key questions were identified to be addressed by the group:

-   What is the role of [egfr]{.smallcaps}-[tkis]{.smallcaps} as first-line therapy of advanced or metastatic [nsclc]{.smallcaps} as a single agent or in combination with chemotherapy?

-   What is the role of [egfr]{.smallcaps}-[tkis]{.smallcaps} following progression after platinum-based chemotherapy (single-agent [egfr]{.smallcaps}-[tki]{.smallcaps} vs. [bsc]{.smallcaps}, [egfr]{.smallcaps}-[tki]{.smallcaps} vs. chemotherapy, and [egfr]{.smallcaps}-[tki]{.smallcaps} in combination with another agent)?

-   Do any patient subpopulations, or clinical and molecular characteristics, predict for additional benefit from [egfr]{.smallcaps}-[tki]{.smallcaps} therapy?

2.1 Literature Search
---------------------

A search of the [medline]{.smallcaps} database for 2000--2007 was conducted using the terms "non-small-cell lung cancer," "epidermal growth factor receptor tyrosine kinase inhibitor," "erlotinib," and "gefitinib." The search excluded articles prior to 2000, because the [egfr]{.smallcaps}-[tkis]{.smallcaps} are new agents and their initial phase [i]{.smallcaps} trials were known to be conducted during the selected time period. Conference proceedings of the American Society of Clinical Oncology 2000--2007 and the International Association for the Study of Lung Cancer 2007 World Conference on Lung Cancer were also searched. Finally, the list of included articles was reviewed by the consensus panel for omissions.

2.2 Study Selection Criteria
----------------------------

Articles published as full reports or as abstracts and conference presentations were included if they focused on

-   [egfr]{.smallcaps}-[tki]{.smallcaps} alone or in combination with chemotherapy in the first-line setting,

-   [egfr]{.smallcaps}-[tki]{.smallcaps} as second- or third-line therapy following progression of platinum-based chemotherapy, or

-   clinical and molecular characteristics that may predict additional benefit from [egfr]{.smallcaps}-[tki]{.smallcaps} therapy.

The literature search results were reviewed by two authors (PE, FK), and articles that met the foregoing criteria were selected for retrieval. The outcomes of interest were overall survival ([os]{.smallcaps}), time to disease progression, tumour response rate, molecular and clinical predictors of benefit from [egfr]{.smallcaps}-[tki]{.smallcaps} therapy, and [qol]{.smallcaps} or symptom improvement. Single-arm phase [ii]{.smallcaps} trials were included only if no data from randomized trials were available. Forty-three individual trials (eight phase [iii]{.smallcaps}, eleven randomized phase [ii]{.smallcaps}, and twenty-four single-agent phase [ii]{.smallcaps} trials) met the eligibility criteria for the present consensus statement. Only studies published in English were considered.

2.3 External Review
-------------------

Final consensus statement draft recommendations were distributed electronically to reviewers. The review panel consisted of practitioners who had attended the consensus meeting and others who were not in attendance. The comments resulting from this review were incorporated into the final document.

3. RECOMMENDATIONS AND KEY EVIDENCE
===================================

3.1 First-Line Treatment
------------------------

What is the role of [egfr]{.smallcaps}-[tkis]{.smallcaps}as first-line therapy of advanced or metastatic [nsclc]{.smallcaps} as a single agent or in combination with chemotherapy?

### 3.1.1 What Is the Role of Single-Agent EGFR-TKIs in Chemonaïve Patients with NSCLC?

#### Key Evidence

Fourteen single-arm phase [ii]{.smallcaps} trials (*n* = 1026) and one randomized phase [ii]{.smallcaps} trial (*n* = 201) evaluated single-agent erlotinib 150 mg or gefitinib 250 mg daily as first-line therapy of stage [iiib]{.smallcaps}/[iv nsclc]{.smallcaps} ([TABLE I](#tI-co16-1-27){ref-type="table"}). In general, patients had an Eastern Cooperative Oncology Group [ps]{.smallcaps} of 0--2 and were not selected for clinical or molecular characteristics reported to be associated with improved response to an [egfr]{.smallcaps}-[tki]{.smallcaps}. Substantial variability was observed in the response rate to single-agent [egfr]{.smallcaps}-[tkis]{.smallcaps} (range: 4%--55%, with an additional 20%--46% achieving disease stabilization). The time to disease progression ranged from 1 month to 6.6 months, with median survival varying between 2.9 months and 14.1 months, and 1-year survival being 24%--58.2% [@b17-co16-1-27]--[@b22-co16-1-27],[@b24-co16-1-27],[@b26-co16-1-27],[@b27-co16-1-27],[@b30-co16-1-27]--[@b36-co16-1-27],[@b38-co16-1-27],[@b39-co16-1-27].

A single randomized placebo-controlled trial compared gefitinib to [bsc]{.smallcaps} in patients with poor performance ([ps]{.smallcaps} 2--3) unsuitable for chemotherapy. The observed response rate was only 6%, and the trial failed to demonstrate significant improvement in either TTP or OS[@b33-co16-1-27].

Among the trials in unselected populations, [qol]{.smallcaps} and symptom improvement data were inconclusive [@b17-co16-1-27]--[@b22-co16-1-27],[@b24-co16-1-27],[@b26-co16-1-27],[@b27-co16-1-27],[@b30-co16-1-27]--[@b36-co16-1-27],[@b38-co16-1-27],[@b39-co16-1-27]. In the single randomized trial, the proportion of patients reporting [qol]{.smallcaps} and symptom improvement appeared similar for gefitinib and [bsc]{.smallcaps} (21.1% vs. 20.0% and 28.3% vs. 23.3% respectively)[@b33-co16-1-27]. Several other authors also reported no significant improvement in [qol]{.smallcaps} over time [@b24-co16-1-27],[@b31-co16-1-27]. However, Spigel reported improvement or no change in [qol]{.smallcaps} \[using the Functional Assessment of Cancer Therapy--Lung ([fact]{.smallcaps}-[l]{.smallcaps})\] in 82% of patients, and improvement or control in lung cancer symptom ([lcs]{.smallcaps}) response in 48% of patients[@b19-co16-1-27]. Pérez--Soler reported significant improvements in pain scores at 2 weeks and improvement in emotional functioning during the first 4 weeks of therapy[@b17-co16-1-27] ([TABLE I](#tI-co16-1-27){ref-type="table"}). In general, these [qol]{.smallcaps} analyses involved small numbers of patients in the absence of control groups and should be interpreted cautiously.

The remaining five phase [ii]{.smallcaps} trials selected patients based on the presence of activating mutations of the *EGFR* gene (*n* = 85) or of clinical characteristics associated with high response rate to treatment (*n* = 40). The trials included patients with stage [iii]{.smallcaps} or [iv nsclc]{.smallcaps} and [ps]{.smallcaps} 0--2, and evaluated either erlotinib 150 mg or gefitinib 250 mg daily. Higher response rates were observed in these selected populations (range: 30%--90%) as compared with the unselected populations described earlier[@b23-co16-1-27],[@b25-co16-1-27],[@b28-co16-1-27],[@b29-co16-1-27],[@b37-co16-1-27],[@b40-co16-1-27]. Longer time to disease progression was also observed (5.6--13.3 months). Median survival was 15.4 months in one trial[@b40-co16-1-27] and was either not reported or not reached in the others [@b23-co16-1-27],[@b25-co16-1-27],[@b28-co16-1-27],[@b29-co16-1-27],[@b37-co16-1-27]. This activity appears encouraging, but randomized trials comparing [egfr]{.smallcaps}-[tki]{.smallcaps} therapy to chemotherapy are needed to draw firm conclusions.

### Consensus Recommendation

The evidence is currently insufficient to recommend first-line single-agent [egfr]{.smallcaps}-[tki]{.smallcaps} therapy in the treatment of advanced or metastatic [nsclc]{.smallcaps}. These recommendations apply both to unselected populations and to patients selected on the basis of activating mutations of the *EGFR* gene or of clinical characteristics predictive of higher response to therapy.

There is evidence of tumour response to single-agent [egfr]{.smallcaps}-[tki]{.smallcaps} as first-line therapy for advanced [nsclc]{.smallcaps}. Response rates to [egfr]{.smallcaps}-[tki]{.smallcaps} therapy appear to be higher in patients selected on the basis of activating mutations of the *EGFR* gene.

Randomized trials are needed to evaluate the effect of first-line [egfr]{.smallcaps}-[tki]{.smallcaps} on survival.

### 3.1.2 What Is the Role of Single-Agent EGFR-TKIs in Patients with Adenocarcinoma with Bronchioloalveolar Features?

#### Key Evidence

The literature search identified a consensus document on systemic therapy of bronchi oloalveolar carcinoma ([bac]{.smallcaps})[@b41-co16-1-27]. It states that there is no evidence to confirm or refute the assertion that the sensitivity of [bac]{.smallcaps} to chemotherapy is any different from that of other histologic subtypes of [nsclc]{.smallcaps}.

Three phase [ii]{.smallcaps} trials in [ps]{.smallcaps} 0--2 patients with stage [iii]{.smallcaps}/[iv bac]{.smallcaps} (*n* = 326) evaluated either erlotinib 150 mg or gefitinib 250 mg daily ([TABLE II](#tII-co16-1-27){ref-type="table"}). Patients were predominantly chemotherapy-naïve. Response rates ranged from 9% to 21%, with disease stabilization in an additional 16%--36%. The survival data demonstrated time to disease progression of between 3.0 months and 3.7 months, and median survival of 13.0--17.1 months[@b42-co16-1-27]--[@b45-co16-1-27]. In one study, shorter progression-free survival ([pfs]{.smallcaps}) and [os]{.smallcaps} were independently associated with non-mucinous as compared with mu-cinous [bac]{.smallcaps} ([pfs]{.smallcaps}: 2.6 months vs. 11.3 months, *p*=0.002; [os]{.smallcaps}: 10.7 months vs. not reached, *p* = 0.003)[@b44-co16-1-27],[@b45-co16-1-27].

#### Consensus Recommendation

There is no evidence to suggest that [bac]{.smallcaps} should be treated differently from other types of [nsclc]{.smallcaps}. The evidence is currently insufficient to recommend [egfr]{.smallcaps}-[tkis]{.smallcaps} as first-line therapy for the treatment of [bac]{.smallcaps}.

### 3.1.3 What Is the Role of First-Line EGFR-TKIs in Combination with Platinum-based Chemotherapy in Patients with NSCLC?

#### Key Evidence

Four large randomized trials evaluated [egfr]{.smallcaps}-[tkis]{.smallcaps} in combination with platinum-based chemotherapy in patients with good [ps]{.smallcaps} with stage [iii]{.smallcaps}/[iv nsclc]{.smallcaps} (*n* = 4348, [TABLE III](#tIII-co16-1-27){ref-type="table"}). Patients were treated with either gemcitabine and cisplatin \[gemcitabine 1250 mg/m^2^ intravenously (IV) on days 1 and 8, and cisplatin 80 mg/m^2^ IV on day 1 of a 21-day cycle\] or carboplatin and paclitaxel \[carboplatin area under the curve ([auc]{.smallcaps}) 6 IV on day 1, and paclitaxel 200 mg/m^2^ IV on day 1 of a 21-day cycle\] with or without erlotinib 150 mg or gefitinib 250 mg or 500 mg daily. Response rates varied between the trials; however, all four trials failed to demonstrate any improvement in response rate with the addition of an [egfr]{.smallcaps}-[tki]{.smallcaps} to platinum-based chemotherapy[@b46-co16-1-27]--[@b49-co16-1-27]. Time to worsening of symptoms did not differ significantly between the groups[@b46-co16-1-27],[@b47-co16-1-27],[@b49-co16-1-27].

No differences were observed in time to disease progression or in median and 1-year survival between patients randomized to chemotherapy alone and those randomized to chemotherapy plus an [egfr-tki]{.smallcaps} (see [TABLE III](#tIII-co16-1-27){ref-type="table"}).[@b46-co16-1-27]--[@b49-co16-1-27]

#### Consensus Recommendation

Clear evidence from four randomized trials shows that concurrent administration of an [egfr]{.smallcaps}-[tki]{.smallcaps} with first-line platinum-based chemotherapy does not prolong survival in unselected patients with [nsclc]{.smallcaps}.

### 3.1.4 What Is the Role of Single-Agent EGFR-TKIs Compared with Chemotherapy in Chemonaïve Patients with NSCLC?

#### Key Evidence

Two randomized trials compared first-line therapy with an [egfr]{.smallcaps}-[tki]{.smallcaps} with chemotherapy in chemonaïve patients with stage [iii]{.smallcaps}/[iv nsclc]{.smallcaps} and [ps]{.smallcaps} 0--2 (*n* = 299, [TABLE IV](#tIV-co16-1-27){ref-type="table"}) [@b50-co16-1-27],[@b52-co16-1-27]. Lilenbaum randomized patients with poor [ps]{.smallcaps} (score of 2) to treatment with either carboplatin and paclitaxel (carboplatin [auc]{.smallcaps} 6 and paclitaxel 200 mg/m^2^ for 4 cycles) or erlotinib 150 mg daily [@b52-co16-1-27]; Crinò randomized elderly patients (more than 70 years of age) to vinorelbine 30 mg/m^2^ IV on days 1 and 8 of a 21-day cycle or gefitinib 250 mg daily[@b50-co16-1-27].

Lilenbaum observed a higher response rate among patients treated with chemotherapy than with erlotinib \[overall response ([or]{.smallcaps}): 12% vs. 2%; [or]{.smallcaps} + stable disease ([sd]{.smallcaps}): 53% vs. 39%\]. Additionally, patients randomized to carboplatin--paclitaxel had a longer time to progression (3.5 months vs. 1.9 months) and a greater survival (9.1 months vs. 6.6 months), although these differences were not statistically significant[@b52-co16-1-27].

Crinò observed similar activity from vinorelbine and gefitinib ([or]{.smallcaps}: 5.1% vs. 3.1%; [or]{.smallcaps}+[sd]{.smallcaps}: 53% vs. 43%). The [pfs]{.smallcaps} favoured vinorelbine, but this difference was not statistically significant \[hazard ratio ([hr]{.smallcaps}): 1.19; 95% confidence interval ([ci]{.smallcaps}): 0.85 to 1.65\]. No difference in overall survival was observed ([hr]{.smallcaps}: 0.98; 95%[ci]{.smallcaps}: 0.66 to 1.47). The groups showed no difference in overall [qol]{.smallcaps} (by [fact]{.smallcaps}-[l]{.smallcaps}) and in [lcs]{.smallcaps}. Gefitinib appeared to be better tolerated than vinorelbine[@b50-co16-1-27].

A third trial evaluated various doses and schedules of erlotinib with carboplatin and paclitaxel[@b51-co16-1-27]. No significant differences were observed among the three treatment groups ([TABLE IV](#tIV-co16-1-27){ref-type="table"}).

#### Consensus Recommendation

The evidence is currently insufficient to recommend the use of an [egfr]{.smallcaps}-[tki]{.smallcaps} over chemotherapy in the first-line therapy of patients with [nsclc]{.smallcaps}. Available evidence raises the possibility that survival of patients with poor [ps]{.smallcaps} treated with first-line [egfr]{.smallcaps}-[tki]{.smallcaps} may be less than that of patients treated with platinum-based chemotherapy.

3.2 Second-Line and Subsequent Treatment for Relapsed or Recurrent Disease
--------------------------------------------------------------------------

What is the role of [egfr]{.smallcaps}-[tkis]{.smallcaps} following progression after platinum-based chemotherapy (single-agent [egfr]{.smallcaps}-[tki]{.smallcaps} vs. [bsc]{.smallcaps}, [egfr]{.smallcaps}-[tki]{.smallcaps} vs. chemotherapy, and [egfr]{.smallcaps}-[tki]{.smallcaps} in combination with another agent)?

### 3.2.1 What Is the Role of EGFR-TKIs as Second- or Third-Line Therapy Following Progression of Platinum-based Chemotherapy?

#### Key Evidence

Two guidelines developed by [cco]{.smallcaps}-[pebc]{.smallcaps}, addressing the role of an [egfr]{.smallcaps}-[tki]{.smallcaps} as subsequent therapy for [nsclc]{.smallcaps}, were identified [@b11-co16-1-27],[@b53-co16-1-27]. Both documents recommend the use of erlotinib as second- or third-line therapy for [nsclc]{.smallcaps} in patients who are not candidates for further chemotherapy.

Four randomized phase [ii]{.smallcaps} and [iii]{.smallcaps} trials in [ps]{.smallcaps} 0--2 patients with stage [iii]{.smallcaps}/[iv nsclc]{.smallcaps} who were not considered candidates for further chemotherapy examined [egfr]{.smallcaps}-[tkis]{.smallcaps} as subsequent therapy following progression of platinum-based chemotherapy (*n* = 2849, [TABLE V](#tV-co16-1-27){ref-type="table"}). Two large phase [iii]{.smallcaps} studies evaluated erlotinib 150 mg ([br]{.smallcaps}.21) or gefitinib 250 mg \[[isel]{.smallcaps} (Iressa Survival Evaluation in Lung Cancer)\] daily compared with placebo [@b56-co16-1-27],[@b57-co16-1-27], and two randomized phase [ii]{.smallcaps} studies \[[ideal]{.smallcaps} 1 and 2 (Iressa Dose Evaluation in Advanced Lung Cancer 1 and 2)\] compared two doses of gefitinib (250 or 500 mg daily)[@b54-co16-1-27],[@b55-co16-1-27]. In the [ideal]{.smallcaps} 1 and 2 trials, no differences were observed in any outcomes examined between gefitinib 250 mg and 500 mg daily.

Results of the [br]{.smallcaps}.21 and [isel]{.smallcaps} trials demonstrated that erlotinib (2.2 months vs. 1.8 months) and gefitinib (3.0 months vs. 2.6 months) significantly prolong time to disease progression [@b56-co16-1-27],[@b57-co16-1-27]. Statistically significant improvements were also seen in [os]{.smallcaps} with erlotinib as compared with placebo (6.7 months vs. 4.7 months, *p* \< 0.001) [@b56-co16-1-27], and a trend toward improved survival was observed with gefitinib (5.6 months vs. 5.1 months, *p* = 0.087) [@b57-co16-1-27].

In the [br]{.smallcaps}.21 trial, patients receiving erlotinib experienced significantly longer time to deterioration in several lung cancer-related symptoms (cough, pain, dyspnea) and in overall physical function [@b58-co16-1-27]. In the [isel]{.smallcaps} trial, a greater proportion of patients randomized to gefitinib experienced improvement in disease-related symptoms (27% vs. 22%). Similarly, patients randomized to gefitinib experienced a significantly greater improvement in [lcs]{.smallcaps} scores (−1.38 vs. −0.86, *p* = 0.019)[@b57-co16-1-27].

#### Consensus Recommendation

In patients with advanced or metastatic [nsclc]{.smallcaps} who are not candidates for further chemotherapy, the use of an [egfr]{.smallcaps}-[tki]{.smallcaps} (as compared with placebo) can result in improved survival. The use of an [egfr]{.smallcaps}-[tki]{.smallcaps} in patients with [nsclc]{.smallcaps} who are not candidates for further chemotherapy can result in significant improvements in disease-related symptoms, and as compared with [bsc]{.smallcaps} alone, can delay time to symptom progression.

### 3.2.2 What Is the Role of EGFR-TKIs Compared with Chemotherapy Following Progression of Platinum-based Chemotherapy?

#### Key Evidence

Seven randomized phase [ii]{.smallcaps} and [iii]{.smallcaps} trials examined an [egfr]{.smallcaps}-[tki]{.smallcaps} as compared with chemotherapy following progression of platinum-based chemotherapy in patients with stage [iii]{.smallcaps}/[iv nsclc]{.smallcaps} and [ps]{.smallcaps} 0--2 (*n* = 2482, [TABLE VI](#tVI-co16-1-27){ref-type="table"}).

One randomized phase [ii]{.smallcaps} trial[@b59-co16-1-27] and two randomized [iii]{.smallcaps} trials phase [@b62-co16-1-27],[@b65-co16-1-27],[@b66-co16-1-27] evaluated gefitinib 250 mg daily vs. docetaxel 60 or 75 mg/m^2^ IV every 3 weeks (*n* = 2096). The response rate with gefitinib was significantly higher than that with docetaxel in a Japanese population (22.5% vs. 12.8%, *p* = 0.009)[@b65-co16-1-27],[@b66-co16-1-27]. However no differences were observed in response rate between gefitinib and docetaxel in the other two trials[@b59-co16-1-27],[@b62-co16-1-27]. No significant differences were observed in [ttp]{.smallcaps} or [os]{.smallcaps} in patients treated with gefitinib or docetaxel. In the trial by Niho *et al.,* the proportion of patients randomized to docetaxel who received third-line [egfr]{.smallcaps}-[tki]{.smallcaps} therapy was greater than the proportion of patients randomized to gefitinib who received third-line chemotherapy. That trial did not meet its primary outcome of non-inferiority of gefitinib (upper limit of 95% [ci]{.smallcaps} ≤ 1.25) as compared with docetaxel ([hr]{.smallcaps}: 1.12; 95% [ci]{.smallcaps}: 0.89 to 1.40)[@b65-co16-1-27],[@b66-co16-1-27]. However, the larger [interest]{.smallcaps} trial (Iressa non-small-cell lung cancer trial evaluating response and survival against Taxotere) demonstrates that gefitinib was non-inferior to docetaxel ([hr]{.smallcaps}: 1.02; 95% [ci]{.smallcaps}: 0.905 to 1.15), in which the definition of non-inferiority accepted a [ci]{.smallcaps} going up to 1.154[@b62-co16-1-27]. The proportion of patients receiving effective third-line therapy was similar between the two treatment arms in that trial.

Another four randomized phase [ii]{.smallcaps} studies evaluated gefitinib 250 mg or erlotinib 150 mg daily with other agents (oral vandetanib 300 mg daily[@b60-co16-1-27]; bortezomib 1.6 mg/m^2^ IV on days 1 and 8 of a 21-day cycle[@b64-co16-1-27]; vinorelbine 15 mg/m^2^ IV on day 1, and gefitinib 250 mg daily on days 2--14 every 2 weeks[@b61-co16-1-27]; bevacizumab 15 mg IV on day 1 every 3weeks; docetaxel 75 mg/m^2^ on day 1 of a 3-week cycle; pemetrexed 500 mg/m^2^ on day 1 of a 3-week cycle)[@b63-co16-1-27] either as single agents or in combination (*n* = 386, [TABLE VI](#tVI-co16-1-27){ref-type="table"}). No firm conclusions can be drawn from any of these trials, although compared with erlotinib alone, the combination of erlotinib plus bevacizumab demonstrated improvement in response rate (17.9% vs. 12.2%), [ttp]{.smallcaps} (4.4 months vs. 3.0 months), and [os]{.smallcaps} (13.7 months vs. 8.6 months)[@b63-co16-1-27]. A phase [iii]{.smallcaps} trial of that combination is ongoing. Fully powered phase [iii]{.smallcaps} trials are ongoing to compare gefitinib with vandetanib and to assess whether bevacizumab adds to the efficacy of single-agent erlotinib.

#### Consensus Recommendation

The evidence suggests that second-line [egfr]{.smallcaps}-[tki]{.smallcaps} or second-line chemotherapy results in similar survival. Sequence does not appear to be important, but if survival is the outcome of interest, the goal should be to optimize the number of patients receiving three lines of effective therapy. The evidence is currently insufficient to recommend second-line therapy with a combination of an [egfr]{.smallcaps}-[tki]{.smallcaps} and another targeted agent. Ongoing randomized phase [iii]{.smallcaps} trials are currently addressing these questions.

### 3.2.3 How Do QOL and Symptom Control Compare in Patients Treated with Chemotherapy as Compared with EGFR-TKIs?

#### Key Evidence

Two of the three trials that compared gefitinib and docetaxel also examined [qol]{.smallcaps} and symptom improvement[@b59-co16-1-27],[@b62-co16-1-27].

In the [sign]{.smallcaps} trial (Second-Line Indication of Gefitinib in [nsclc]{.smallcaps}), a greater proportion of patients randomized to gefitinib experienced symptom improvement as assessed by [lcs]{.smallcaps} (36.8% vs. 26%) and [qol]{.smallcaps} improvement as assessed by the [fact]{.smallcaps}-[l]{.smallcaps} (33.8% vs. 26%)[@b59-co16-1-27]. In addition, in the [interest]{.smallcaps} trial, significantly more patients randomized to the gefitinib arm showed improvements in [fact]{.smallcaps}-[l]{.smallcaps} score (25.1% vs. 14.7%, *p* \< 0.0001) and trial outcome index (17.3% vs. 10.3%, *p* = 0.0026). Symptom improvement rates were also better with gefitinib than with docetaxel, but this difference was not statistically significant[@b62-co16-1-27].

#### Key Recommendation

Symptom control and [qol]{.smallcaps} appear to be better in patients treated with an [egfr]{.smallcaps}-[tki]{.smallcaps} than in those treated with either [bsc]{.smallcaps} or second-line chemotherapy with docetaxel. In decisions about treatment following failure of platinum-based chemotherapy, [qol]{.smallcaps} and patient choice are important.

### 3.2.4 What Is the Role of Single-Agent EGFR-TKI Therapy in Previously Treated Patients with EGFR Gene Mutations or High Gene Copy, or EGFR Protein Expression?

#### Key Evidence

Four single-arm phase [ii]{.smallcaps} trials evaluated gefitinib 250 mg daily in patient populations (n = 117) selected for the presence of activating mutations of the *EGFR* gene assessed by polymerase chain reaction ([pcr]{.smallcaps}) analysis or for high *EGFR* gene copy assessed using fluorescence *in situ* hybridization ([fish]{.smallcaps}). Patients had stage [iii]{.smallcaps}/[iv]{.smallcaps} disease and [ps]{.smallcaps} 0--2, and most had received prior chemotherapy. High response rates were observed (48%--90%)[@b67-co16-1-27]--[@b70-co16-1-27]. Time to disease progression ranged from 6.4 months to 12.9 months, with a median survival of 15.5 months reported in one study[@b69-co16-1-27]. Given that *EGFR* mutations are thought to represent a favourable prognostic factor, the significance of these data are unclear, and randomized trials are needed to determine if the survival of patients with *EGFR* mutations or high *EGFR* gene copy treated with an [egfr]{.smallcaps}-[tki]{.smallcaps} is superior to that of similar patients treated with second-line chemotherapy.

#### Consensus Recommendations

There is evidence that patients with previously treated [nsclc]{.smallcaps} and *EGFR* mutations or increased *EGFR* gene copy respond to an [egfr]{.smallcaps}-[tki]{.smallcaps}. However, the evidence is insufficient at this time to select patients for [egfr]{.smallcaps}-[tki]{.smallcaps} therapy rather than for second-line chemotherapy based on any *EGFR* marker.

3.3 Clinical and Molecular Predictors of Benefit
------------------------------------------------

Do any patient subpopulations, or clinical and molecular characteristics, predict for additional benefit from [egfr]{.smallcaps}-[tki]{.smallcaps} therapy?

### 3.3.1 What Are the Molecular Characteristics that Predict Additional Benefit from egfr-tki Therapy?

#### Key Evidence

##### Clinical Predictors of Response to an [egfr]{.smallcaps}*-*[tki]{.smallcaps}

[TABLE VII](#tVII-co16-1-27){ref-type="table"} summarizes the trials examining clinical predictors of response. Data are available from the [ideal]{.smallcaps} 1, [ideal]{.smallcaps} 2, [br]{.smallcaps}.21, and [isel]{.smallcaps} trials. Analyses from the [ideal]{.smallcaps} 1 and 2 trials demonstrated that ad-enocarcinoma (13% vs.4%) and female sex (19% vs. 3%) both significantly predict response to gefitinib[@b55-co16-1-27]. Additional clinical predictors of response were observed in the [br]{.smallcaps}.21 trial. In that study, clinical characteristics associated with higher response to erlotinib included adenocarcinoma (13.9% vs. 4.1%, *p* \< 0.001), never smokers (24.7% vs. 3.9%, *p* \< 0.001), female sex (14.4% vs. 6%, *p* = 0.006), and Asian ethnicity (*n* = 427: 18.9% vs. 7.5%, *p* = 0.002)[@b56-co16-1-27],[@b71-co16-1-27]--[@b73-co16-1-27]. Consistent with the [br]{.smallcaps}.21 results, subset analysis from the [isel]{.smallcaps} trial also demonstrated that adenocarcinoma (11.9% vs. 4.8%), never smokers (18.1% vs. 5.3%), female sex (14.7% vs. 5.1%), and Asian ethnicity (12.4% vs. 7.5%) were predictors of response to gefitinib (*n* = 1439)[@b57-co16-1-27].

##### Clinical Predictors of Survival with an [egfr]{.smallcaps}-[tki]{.smallcaps}

[TABLE VIII](#tVIII-co16-1-27){ref-type="table"} summarizes clinical predictors of survival for patients receiving therapy with an [egfr]{.smallcaps}-[tki]{.smallcaps} [@b57-co16-1-27],[@b71-co16-1-27]--[@b79-co16-1-27]. In the [br]{.smallcaps}.21 trial, the only clinical characteristic that predicted greater effect on survival for erlotinib as compared with supportive care alone was a history of never having smoked ([hr]{.smallcaps}: 0.4 vs. 0.9; *p* = 0.02). There was no evidence of any differential survival effect for histology ([hr]{.smallcaps}: 0.7 adenocarcinoma vs. 0.8 non-adenocarcinoma), sex ([hr]{.smallcaps}: 0.8 males vs. 0.8 females), or ethnicity ([hr]{.smallcaps}: 0.6 Asian vs. 0.8 non-Asian) [@b71-co16-1-27]--[@b73-co16-1-27],[@b77-co16-1-27],[@b78-co16-1-27]. The [isel]{.smallcaps} trial demonstrated significantly improved survival among patients randomized to gefitinib for never smokers ([hr]{.smallcaps}: 0.67; 95% [ci]{.smallcaps}: 0.49 to 0.92) and for patients of Asian ethnicity ([hr]{.smallcaps}: 0.66; 95%[ci]{.smallcaps}: 0.48 to 0.91)[@b57-co16-1-27]. There was a trend toward improved survival for patients with adenocarcinoma treated with gefitinib ([hr]{.smallcaps}: 0.84; 95% [ci]{.smallcaps}: 0.70 to 1.02). In a subset analysis of all Asian patients from the [isel]{.smallcaps} trial, significant improvements in survival were seen for patients with adenocarcinoma ([hr]{.smallcaps}: 0.66 vs. 0.86), never smokers ([hr]{.smallcaps}: 0.37 vs. 0.85), and female sex ([hr]{.smallcaps}: 0.46 vs. 0.80)[@b76-co16-1-27].

No data were available concerning clinical predictors of survival from the [intact]{.smallcaps} (Iressa [nsclc]{.smallcaps} Trial Assessing Combination Treatment) 1 and 2 trials[@b80-co16-1-27]. In a subset analysis of never smokers (*n* = 113) from the [tribute]{.smallcaps} (Tarceva Responses in Conjunction with Paclitaxel and Carboplatin) trial, a significant improvement in survival was observed from the addition of erlotinib ([hr]{.smallcaps}: 0.49; 95% [ci]{.smallcaps}: 0.28 to 0.85) [@b81-co16-1-27]. Similar findings were observed in [talent]{.smallcaps} (Tarceva Lung Cancer Investigation Trial). Improved [os]{.smallcaps} and [pfs]{.smallcaps} were observed for patients receiving erlotinib who had never smoked ([hr]{.smallcaps}: 0.39; *p* = 0.25), although this interaction did not achieve statistical significance[@b74-co16-1-27],[@b75-co16-1-27].

In contrast, subgroup analyses from the [interest]{.smallcaps} trial comparing gefitinib with docetaxel suggest that these clinical variables do not predict a differential benefit for an [egfr]{.smallcaps}-[tki]{.smallcaps} over chemotherapy. There was no difference in the survival of patients with adenocarcinoma histology, never smokers, Asian ethnicity, and female sex when treated with either gefitinib or docetaxel[@b79-co16-1-27].

##### Molecular Predictors of Response to an [egfr]{.smallcaps}-[tki]{.smallcaps}

The predictive value of various molecular abnormalities have been examined in the randomized trials included in the present consensus document. These include mutations of the *EGFR* gene, increased *EGFR* gene copy assessed by [fish]{.smallcaps} or *EGFR* amplification assessed by quantitative [pcr]{.smallcaps}, [egfr]{.smallcaps} expression \[by immunohistochemistry ([ihc]{.smallcaps})\], and mutations of the *KRAS* gene. [TABLE IX](#tIX-co16-1-27){ref-type="table"} summarizes predictors of response.

The presence of an activating mutation of the *EGFR* gene is associated with an increased likelihood of response to single-agent [egfr]{.smallcaps}-[tki]{.smallcaps}. Analyses of tumour samples from the [ideal]{.smallcaps} 1 and 2 trials (*n* = 425) evaluating gefitinib monotherapy demonstrated that patients whose tumour had an *EGFR* mutation had a better [or]{.smallcaps} with gefitinib than did patients lacking the mutation (*n* = 79: 46% vs.10%, *p* = 0.005)[@b80-co16-1-27]. In the [br]{.smallcaps}.21 (*n* = 177: 15.8% vs. 7.4%, *p* = 0.35) and [isel]{.smallcaps} trials (*n* = 215: 37.5% vs. 2.6%), the presence of an *EGFR* mutation was associated with a nonsignificant increase in response rate. In [br]{.smallcaps}.21, when only exon 19 deletion and L858R mutations were considered, the difference in response rate as compared with wild-type *EGFR* or other mutations was significant (27% vs. 7%, *p* = 0.035)[@b85-co16-1-27]. The subset analysis of tumour samples from the [intact]{.smallcaps} 1 and 2 trials evaluating the addition of gefitinib to standard first-line chemotherapies demonstrated that patients whose tumours had an *EGFR* mutation had a higher response to chemotherapy plus gefitinib than did those without a mutation (*n* = 170: 72% vs. 55%, *p* = 0.2)[@b80-co16-1-27]. Similar findings were observed in the [tribute]{.smallcaps} trial for patients with *EGFR* mutations (*n* = 228: 53% vs. 21%, *p* \< 0.01)[@b82-co16-1-27],[@b84-co16-1-27], but no statistically significant correlation was observed between response rates and mutation status in the [talent]{.smallcaps} trial[@b74-co16-1-27],[@b75-co16-1-27].

Increased *EGFR* gene copy or *EGFR* amplification also appears to be associated with an increased response rate to single-agent [egfr]{.smallcaps}-[tki]{.smallcaps}. The [ideal]{.smallcaps} 1 and 2 trials demonstrated that *EGFR* amplification was associated with a higher response to gefitinib than was seen with tumours without *EGFR* amplification; however, this difference was not statistically significant (*n* = 90: risk ratio: 29% vs.15%; *p* = 0.319). Patients with an *EGFR* mutation or gene amplification had a significantly improved response rate as compared with patients with neither *EGFR* amplification nor mutation (60% vs. 10%, *p* = 0.0011)[@b80-co16-1-27]. Within the [br]{.smallcaps}.21 trial, high *EGFR* gene copy or amplification also was associated with a significantly higher response to erlotinib (*n* = 91: 21% vs. 5%, *p* = 0.02)[@b71-co16-1-27],[@b77-co16-1-27],[@b85-co16-1-27]. Similar findings were observed in the [isel]{.smallcaps} trial (*n* = 317: 16.4% vs. 3.2%)[@b83-co16-1-27].

In [intact]{.smallcaps} 1 and 2, there were no differences in response with and without *EGFR* amplification (n = 235: 56% vs. 53%, *p* \> 0.05)[@b80-co16-1-27]. Interestingly, analysis of tumour samples from the [tribute]{.smallcaps} study demonstrated a lower response rate among patients whose tumours demonstrated *EGFR* amplification[@b82-co16-1-27],[@b84-co16-1-27]. It is important to note that [fish]{.smallcaps} was used to assess *EGFR* gene copy status in the [br]{.smallcaps}.21, [isel]{.smallcaps}, and [tribute]{.smallcaps} studies[@b82-co16-1-27]--[@b85-co16-1-27], but that quantitative [pcr]{.smallcaps} was used in the [ideal]{.smallcaps} and [intact]{.smallcaps} studies[@b80-co16-1-27]. High *EGFR* gene copy by [fish]{.smallcaps} includes cases of *EGFR* high polysomy and of *EGFR* amplification alike[@b82-co16-1-27]--[@b85-co16-1-27], but quantitative [pcr]{.smallcaps} results include cases of *EGFR* gene amplification only[@b80-co16-1-27]. Thus, the two results are not entirely comparable.

Fewer data are available concerning the predictive value of [egfr]{.smallcaps} protein expression. In both the [br]{.smallcaps}.21 (*n* = 142: 11% vs. 4%, *p*= 0.1)[@b85-co16-1-27] and [isel]{.smallcaps} trials (*n* = 303: 8.2% vs. 3.2%)[@b83-co16-1-27], higher response rates to erlotinib were demonstrated for patients with [egfr]{.smallcaps} expression. However, the presence of *KRAS* mutations appears to be associated with a lower chance of tumour response. Lower response rates were observed in the [br]{.smallcaps}.21 (*n* = 118: 5% vs. 10%, *p* = 0.069)[@b85-co16-1-27], [isel]{.smallcaps} (*n* = 93: 0% vs. 8%)[@b83-co16-1-27], and [tribute]{.smallcaps} trials (*n* = 264: 8% vs. 23%, *p* = 0.16)[@b82-co16-1-27],[@b84-co16-1-27], although none of those results was statistically significant.

##### Molecular Predictors of Survival

[TABLE X](#tX-co16-1-27){ref-type="table"} summarizes trials examining molecular predictors of survival for patients treated with an [egfr]{.smallcaps}-[tki]{.smallcaps} [@b71-co16-1-27],[@b74-co16-1-27],[@b75-co16-1-27],[@b77-co16-1-27],[@b80-co16-1-27],[@b82-co16-1-27]--[@b86-co16-1-27]. No single molecular marker has consistently been associated with improved survival for patients treated with an [egfr]{.smallcaps}-[tki]{.smallcaps}.

The [ideal]{.smallcaps} 1 and 2 trials, [br]{.smallcaps}.21, and [isel]{.smallcaps} all examined single-agent [egfr]{.smallcaps}-[tkis]{.smallcaps} [@b71-co16-1-27],[@b77-co16-1-27],[@b83-co16-1-27],[@b85-co16-1-27]. Analysis of tumour samples from [ideal]{.smallcaps} 1 and 2 showed no significant improvement in [ttp]{.smallcaps} or survival for patients with *EGFR* mutations or with *EGFR* amplification[@b80-co16-1-27]. However, these trials were not designed to examine predictors of survival, given that both groups of patients received an [egfr]{.smallcaps}-[tki]{.smallcaps} [@b80-co16-1-27].

The [br]{.smallcaps}.21 trial generated several reports of molecular analyses[@b71-co16-1-27],[@b77-co16-1-27],[@b85-co16-1-27]. On univariate analyses, there was no evidence that the survival benefit of erlotinib was influenced significantly by [egfr]{.smallcaps} expression (*n* = 325: [ihc]{.smallcaps} + [hr]{.smallcaps}: 0.68; [ihc]{.smallcaps}^−^ [hr]{.smallcaps}: 0.93; *p* = 0.1), increased *EGFR* gene copy (*n* = 159: [fish]{.smallcaps}^+^ [hr]{.smallcaps}: 0.43; [fish]{.smallcaps}^−^ [hr]{.smallcaps}: 0.80; interaction *p* = 0.12), or *EGFR* mutation status (*n* = 204: mut^+^ [hr]{.smallcaps}: 0.55; mut^−^ [hr]{.smallcaps}: 0.74; interaction *p* = 0.47). However, in multivariate analysis, increased *EGFR* gene copy was prognostic for poorer survival (*p* = 0.0025) and predictive of a differential survival benefit from erlotinib (*p* = 0.005)[@b71-co16-1-27],[@b77-co16-1-27],[@b85-co16-1-27].

The molecular analysis of the [isel]{.smallcaps} trial demonstrated a differential effect of gefitinib on survival according to *EGFR* gene copy (*n* = 370: [fish]{.smallcaps} + [hr]{.smallcaps} 0.61 vs. [fish]{.smallcaps}^−^ [hr]{.smallcaps} 1.16; interaction *p* = 0.045) and [egfr]{.smallcaps} expression (*n* = 379: [ihc]{.smallcaps} + [hr]{.smallcaps}: 0.77; [ihc]{.smallcaps}^−^ [hr]{.smallcaps}: 1.57; interaction *p* = 0.049). The data were insufficient for a survival analysis for patients with and without *EGFR* mutations[@b83-co16-1-27].

Molecular analyses are available from all four trials evaluating the addition of an [egfr]{.smallcaps}-[tki]{.smallcaps} to platinum-based chemotherapy. The addition of gefitinib to chemotherapy did not significantly improve [os]{.smallcaps} in patients with ([hr]{.smallcaps}: 2.03; 95% [ci]{.smallcaps}: 0.67 to 6.13) or without ([hr]{.smallcaps}: 1.01; 95% [ci]{.smallcaps}: 0.79 to 1.29) *EGFR* amplification (*n* = 453), or with ([hr]{.smallcaps}: 1.77; 95% [ci]{.smallcaps}: 0.5 to 6.2) and without ([hr]{.smallcaps}: 0.91; 95% [ci]{.smallcaps}: 0.67 to 1.23) *EGFR* mutations (*n* = 312)[@b86-co16-1-27].

Survival analysis from the [tribute]{.smallcaps} trial demonstrated a borderline improvement in [ttp]{.smallcaps} for patients receiving chemotherapy plus erlotinib ([ttp hr]{.smallcaps}: 0.59; 95% [ci]{.smallcaps}: 0.35 to 0.99), but no difference in [os]{.smallcaps} for patients with *EGFR* amplification (*n* = 245) [@b82-co16-1-27],[@b84-co16-1-27]. In patients with an *EGFR* mutation, there was also a trend toward improved [ttp]{.smallcaps} (12.5 months vs. 6.6 months, *p* = 0.092), but no difference in [os]{.smallcaps} was demonstrated (*p* = 0.96, *n* = 274)[@b82-co16-1-27],[@b83-co16-1-27]. Similar findings were observed in the [talent]{.smallcaps} study. The presence of *EGFR* mutations did not predict for improved [os]{.smallcaps} (*p* = 0.65 for placebo vs. *p* = 0.40 for erlotinib) and [pfs]{.smallcaps} (*p* = 0.74 for placebo vs. *p* = 0.18 for erlotinib) irrespective of treatment[@b74-co16-1-27],[@b75-co16-1-27].

Information is more consistent that the presence of *KRAS* mutations is associated with worse survival for patients receiving an [egfr]{.smallcaps}-[tki]{.smallcaps}. Results from [br]{.smallcaps}.21 demonstrated a trend towards worse survival for patients on erlotinib with *KRAS* mutations (*n* = 206: *KRAS*^+^ [hr]{.smallcaps}: 1.67; *KRAS*^−^ [hr]{.smallcaps}: 0.69; *p* = 0.09) [@b71-co16-1-27],[@b77-co16-1-27],[@b85-co16-1-27]. Similarly, *KRAS* mutations predicted poor overall survival in erlotinib-treated patients on the [talent]{.smallcaps} trial [@b74-co16-1-27],[@b75-co16-1-27]. In addition, data from the [tribute]{.smallcaps} trial demonstrated that the presence of *KRAS* mutations was associated with significantly decreased [ttp]{.smallcaps} and survival in patients randomized to erlotinib plus chemotherapy (*n* = 274: [hr]{.smallcaps}: 2.1; 95% [ci]{.smallcaps}: 1.1 to 3.8; 4.4 months vs. 13.5 months *KRAS*^+^ vs. 12.1 months vs. 11.3 months *KRAS*^−^, *p* = 0.019\][@b82-co16-1-27],[@b84-co16-1-27].

In contrast, there is no evidence that these molecular markers predict a differential effect on survival from an [egfr]{.smallcaps}-[tki]{.smallcaps} than from chemotherapy. The molecular analyses from the [interest]{.smallcaps} trial showed no significant differences in survival between patients treated with gefitinib or with docetaxel according to [egfr]{.smallcaps} expression, *EGFR* gene copy, *EGFR* mutational status, or *KRAS* status[@b79-co16-1-27].

#### Consensus Recommendation

Molecular markers such as *EGFR* high gene copy or *EGFR* mutations and clinical characteristics such as adenocarcinoma, female sex, never smoking, and Asian ethnicity appear to be associated with a higher likelihood of response to an [egfr]{.smallcaps}-[tki]{.smallcaps}. The evidence is currently insufficient to select patients based on molecular markers predictive of improved survival with an [egfr]{.smallcaps}-[tki]{.smallcaps}. Prospective data will be needed before further recommendations can be made.

The evidence is conflicting about the predictive value of clinical characteristics for survival. However, the data suggest that the survival benefit of an [egfr]{.smallcaps}-[tki]{.smallcaps} may be greater among never smokers. Based on available data, molecular markers and clinical characteristics should not be used to exclude patients from receiving [egfr]{.smallcaps}-[tki]{.smallcaps} therapy.

4. DISCUSSION
=============

The [egfr]{.smallcaps}-[tkis]{.smallcaps} of represent a significant advance in the management of advanced and metastatic [nsclc]{.smallcaps}. Not only do they have activity in [nsclc]{.smallcaps}, they also appear to have an improved toxicity profile as compared with standard chemotherapy agents such as docetaxel. As a result, they offer an attractive therapeutic option. Nevertheless, it is important that these agents be incorporated into routine treatment algorithms based on appropriate data from randomized trials.

It is clear that [egfr]{.smallcaps}-[tkis]{.smallcaps} should not be used concomitantly with standard chemotherapy agents in the treatment of [nsclc]{.smallcaps}. The strongest evidence supporting their use is in patients who have progressed following platinum-based chemotherapy. It is appealing to think that use of an [egfr]{.smallcaps}-[tki]{.smallcaps} may spare patients the toxicity of more chemotherapy. However, available data support the use of second-line chemotherapy and third-line [egfr]{.smallcaps}-[tki]{.smallcaps} or second-line [egfr]{.smallcaps}-[tki]{.smallcaps} and then third-line chemotherapy. Because both approaches prolong survival, the goal of therapy in advanced [nsclc]{.smallcaps} should be to maximize the number of patients who receive three lines of therapy, if survival is the outcome of interest. However, some patients will choose not to have second-line chemotherapy, and so the sequence of therapies should reflect a discussion between the physician and the patient regarding the relative benefits and side effects of each treatment option.

Multiple reports in the literature suggest that molecular markers and clinical characteristics can be used to select patients who will be more likely to benefit from an [egfr]{.smallcaps}-[tki]{.smallcaps}. However, this literature comes with significant limitations. The term "benefit" creates confusion, because it is used to refer to a variety of outcomes, including tumour response, improved [os]{.smallcaps}, and improved symptom control and [qol]{.smallcaps}. The molecular analyses are limited to patients whose tumour samples were available. The percentage of patients whose samples were available for one or more molecular analyses ranged from 25% to 44% of the total study population. As a result, some of these comparisons involve small numbers of patients. In addition, much of the literature has focused on tumour response rates, rather than on survival. Although there is some consistency in factors predicting response, these factors do not correlate directly with variables predicting a **differential** benefit in survival. Considerable variation is found in the variables reported to be associated with a differential improvement in survival from therapy with an [egfr]{.smallcaps}-[tki]{.smallcaps}. This variation may exist in part because some of the [egfr]{.smallcaps} markers are prognostic and associated with trends toward better survival (some *EGFR* mutations) or worse survival (high *EGFR* copy number). Therefore, it is not possible to assess the effect of [egfr]{.smallcaps}-[tki]{.smallcaps} therapy on survival in the absence of a no-treatment control arm. Furthermore, markers that seem to predict for a differential survival benefit when [egfr]{.smallcaps}-[tki]{.smallcaps} therapy is compared with placebo or no treatment may not be predictive when [egfr]{.smallcaps}-[tki]{.smallcaps} therapy is compared with another form of treatment such as chemotherapy. As a result, the evidence is currently insufficient to recommend the routine use of molecular markers and clinical characteristics to select patients for therapy with an [egfr]{.smallcaps}-[tki]{.smallcaps}. It is therefore also premature to recommend the use of single-agent [egfr]{.smallcaps}-[tkis]{.smallcaps} as first-line therapy for [nsclc]{.smallcaps}, even in patients selected on basis of molecular and clinical characteristics.

These results highlight the need for prospective trials in which tumour samples are available for all patients, so as to address correlative questions. Ongoing research will also address questions concerning the sequence of platinum-based chemotherapy or [egfr]{.smallcaps}-[tki]{.smallcaps} as first-line therapy.

Since the literature search for the present review was completed, preliminary data from two trials of maintenance gefitinib or erlotinib in Asian populations were presented at the American Society of Clinical Oncology Annual Scientific Meeting in 2008[@b87-co16-1-27],[@b88-co16-1-27]. Both trials showed improved [pfs]{.smallcaps}, but no significant improvements in [os]{.smallcaps}. In addition, initial results of [ipass]{.smallcaps} (Iressa Pan ASia Study) were presented at the 2008 meeting of the European Society for Medical Oncology[@b89-co16-1-27]. That trial compared first-line gefitinib with carboplatin and paclitaxel in light- or never-smoking Asian patients. A significant improvement was observed in [pfs]{.smallcaps}, but no significant difference in [os]{.smallcaps}. Other ongoing trials are evaluating the role of an [egfr]{.smallcaps}-[tki]{.smallcaps} as maintenance therapy in patients responding to first-line platinum-based chemotherapy.

Lastly, chemotherapy experience suggests that the therapeutic ratio can be improved with combination therapy. Preliminary evidence suggests that combination therapy with an [egfr]{.smallcaps}-[tki]{.smallcaps} and agents active against vascular endothelial growth factor may have greater activity. These questions are being addressed in multiple ongoing clinical trials. Participation in these trials should be encouraged.

This consensus statement was supported by an unrestricted educational grant from Hoffmann--La Roche Limited. The recommendations are those of the participants and are independent of Hoffmann--La Roche.

###### 

Trials of single-agent epidermal growth factor receptor tyrosine kinase inhibitors ([egfr]{.smallcaps}-[tkis]{.smallcaps}) in chemonaïve patients with non-small-cell lung cancer

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                                                                                                                                                                                                                                                                                                                                                     Survival                                                    
  ------------------------------------------------------------------------------------ ----------------------------------- -------------------------- --------------------------------------------------------------------------------- ------------ ------------------ ------------------ -------------------------------------------------------------------------------------------- ------------------------------------------------------------ ----------------------------------------------------------- ---------------------------------------------
  Pérez--Soler *et al.*, 2004[@b17-co16-1-27]                                          Phase [ii]{.smallcaps}              Erlotinib 150 mg           Unselected                                                                        57           15.8/84.2          87.7/12.3          12[a](#tfn1-co16-1-27){ref-type="table-fn"}/35/49                                            9 Weeks                                                      8.4 Months[a](#tfn1-co16-1-27){ref-type="table-fn"}         40

  Kasahara *et al.*, 2005[@b18-co16-1-27]                                              Phase [ii]{.smallcaps}              Gefitinib 250 mg           Unselected Asian                                                                  30           [nr]{.smallcaps}   [nr]{.smallcaps}   33/30                                                                                        3.3 Months                                                   10 Months                                                   43.3

  Spigel *et al.*, 2005[@b19-co16-1-27]                                                Phase [ii]{.smallcaps}              Gefitinib 250 mg           Unselected                                                                        72           [nr]{.smallcaps}   0/83               4[b](#tfn2-co16-1-27){ref-type="table-fn"}/46/26                                             3.7 Months                                                   6.3 Months                                                  24

  Swinson *et al.*, 2005[@b20-co16-1-27]                                               Phase [ii]{.smallcaps}              Gefitinib 250 mg           Unselected                                                                        45           [nr]{.smallcaps}   17/27              9.8/36.6/53.4                                                                                32 Days                                                      82 Days                                                     [nr]{.smallcaps}

  Akerley, 2006 [@b21-co16-1-27] and\\Akerley et al., 2006[@b22-co16-1-27]             Phase [ii]{.smallcaps}              Erlotinib 150 mg           Unselected                                                                        40           [nr]{.smallcaps}   100/0              15[b](#tfn2-co16-1-27){ref-type="table-fn"}/28/58[c](#tfn3-co16-1-27){ref-type="table-fn"}   22 Weeks                                                     49 Weeks[c](#tfn3-co16-1-27){ref-type="table-fn"}           49[c](#tfn3-co16-1-27){ref-type="table-fn"}

  Asahina *et al.*, 2006[@b23-co16-1-27]                                               Phase [ii]{.smallcaps}              Gefitinib 250 mg           Selected ([egfr]{.smallcaps}^+^)[d](#tfn4-co16-1-27){ref-type="table-fn"} Asian   16           [nr]{.smallcaps}   [nr]{.smallcaps}   75/6/19                                                                                      8.9 Months                                                   Not reached                                                 Not reached

  Giaccone *et al.*, 2006[@b24-co16-1-27]                                              Phase [ii]{.smallcaps}              Erlotinib 150 mg           Unselected                                                                        53           21/79              85/15              23/30/23 (84 days)                                                                           3.0 Months (391 Days)                                        13.9 Months                                                 54

  Inoue *et al.*, 2006[@b25-co16-1-27]                                                 Phase [ii]{.smallcaps}              Gefitinib 250 mg           Selected ([egfr]{.smallcaps}^+^)[d](#tfn4-co16-1-27){ref-type="table-fn"} Asian   16           0/63               88/12              75[b](#tfn2-co16-1-27){ref-type="table-fn"}/12.5/12.5                                        9.7 Months                                                   [nr]{.smallcaps}                                            [nr]{.smallcaps}

  Lin *et al.*, 2006[@b26-co16-1-27]                                                   Phase [ii]{.smallcaps}              Gefitinib 250 mg           Unselected Asian                                                                  53           13/87              76/9               32[b](#tfn2-co16-1-27){ref-type="table-fn"}/21/47                                            3.2 Months                                                   9.4 Months                                                  41.5

  Niho *et al.*, 2006[@b27-co16-1-27]                                                  Phase [ii]{.smallcaps}              Gefitinib 250 mg           Unselected Asian                                                                  42           8/85               100/0              30[b](#tfn2-co16-1-27){ref-type="table-fn"}/40/30                                            [nr]{.smallcaps}                                             13.9 Months                                                 55

  Paz--Ares *et al.*, 2006[@b28-co16-1-27],[@b29-co16-1-27]                            Phase [ii]{.smallcaps}              Erlotinib 150 mg           Selected ([egfr]{.smallcaps}^+^)[d](#tfn4-co16-1-27){ref-type="table-fn"}         37           10/90              33/55              90/5/5[c](#tfn3-co16-1-27){ref-type="table-fn"}                                              13.3 Months                                                  [nr]{.smallcaps}                                            82

  Reck *et al.*, 2006[@b30-co16-1-27]                                                  Phase [ii]{.smallcaps}              Gefitinib 250 mg           Unselected                                                                        58           [nr]{.smallcaps}   76/24              5/40/52                                                                                      7 Weeks                                                      29 Weeks                                                    

  Suzuki *et al.*, 2006 [@b31-co16-1-27]                                               Phase [ii]{.smallcaps}              Gefitinib 250 mg           Unselected Asian                                                                  34           0/100              100/0              26.5/23.5                                                                                    [nr]{.smallcaps}                                             14.1 Months                                                 58.2

  Yang *et al.*, 2006 [@b32-co16-1-27]                                                 Phase [ii]{.smallcaps}              Gefitinib 250 mg           Unselected Asian                                                                  44           [nr]{.smallcaps}   40/4               54.5/20                                                                                      6.3 Months                                                   [nr]{.smallcaps}                                            [n]{.smallcaps}

  Goss *et al.*, 2007 [@b33-co16-1-27]                                                 Randomized phase [ii]{.smallcaps}   Gefitinib 250 mg Placebo   Unselected                                                                        100\         [nr]{.smallcaps}   0/100              6.0/--/not available\                                                                        [hr]{.smallcaps}: 0.82 95% [ci]{.smallcaps}: 0.60 to 1.12\   [hr]{.smallcaps}: 0.84 95% [ci]{.smallcaps}: 0.62 to 1.15   
                                                                                                                                                                                                                                        101                                                1.0/--/not available\                                                                        *p*=0.272                                                                                                                
                                                                                                                                                                                                                                                                                           *p*=[ns]{.smallcaps}\                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                           *p*=0.217                                                                                                                                                                                                             

  Hesketh *et al.*, 2007[@b34-co16-1-27],[@b35-co16-1-27] ([swog]{.smallcaps} S0341)   Phase [ii]{.smallcaps}              Erlotinib 150 mg           Unselected                                                                        82           12/88              0/100              7[b](#tfn2-co16-1-27){ref-type="table-fn"}/36/42[c](#tfn3-co16-1-27){ref-type="table-fn"}    2 Months                                                     6 Months                                                    24

  Jackman *et al.*, 2007[@b36-co16-1-27]                                               Phase [ii]{.smallcaps}              Erlotinib 150 mg           Unselected, ≥70 years of age                                                      80           15/85              90/10              10/41/35                                                                                     3.5 Months                                                   10.9 Months                                                 46

  Jackman *et al.*, 2007[@b37-co16-1-27]                                               Phase [ii]{.smallcaps}              Erlotinib 150 mg           Selected based on patient characteristics                                         40 (women)   [nr]{.smallcaps}   100/0              30[b](#tfn2-co16-1-27){ref-type="table-fn"}/28/25                                            5.6 Months                                                   Not reached (exceeds 23 Months)                             [nr]{.smallcaps}

  Jimenez *et al.*, 2007[@b38-co16-1-27],[@b39-co16-1-27]                              Phase [ii]{.smallcaps}              Erlotinib 150 mg           Unselected                                                                        437          24/76              70/30              31                                                                                           6.6 Months                                                   7.1 Months                                                  [nr]{.smallcaps}

  Sugio *et al.*, 2007[@b40-co16-1-27]                                                 Phase [ii]{.smallcaps}              Gefitinib 250 mg           Selected ([egfr]{.smallcaps}^+^)[d](#tfn4-co16-1-27){ref-type="table-fn"} Asian   16           [nr]{.smallcaps}   [nr]{.smallcaps}   50/33/not available                                                                          8.8 Months                                                   15.4                                                        
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Predictor of overall response (multivariate analysis): time from last chemotherapy (*p* = 0.033); predictors of survival (multivariate analysis): time from initial diagnosis (*p* = 0.0007); good performance status \[PS 0--1/2 (*p* = 0.04)\].

Partial response.

14 Patients could not be evaluated, and 1 patient experienced early death.

Selected based on presence of [egfr]{.smallcaps} mutations.

[ps]{.smallcaps} = performance status; [or]{.smallcaps} = overall response (complete response + partial response); [sd]{.smallcaps} = stable disease; [pd]{.smallcaps} = progressive disease; [ttp]{.smallcaps} = median time to progression; [pfs]{.smallcaps} = median progression-free survival; [nr]{.smallcaps} = not recorded; [hr]{.smallcaps} = hazard ratio; [ci]{.smallcaps} = confidence interval; [swog]{.smallcaps} = Southwest Oncology Group.

###### 

Trials involving patients with adenocarcinoma with features of bronchioloalveolar carcinoma ([bac]{.smallcaps})

                                                                                                                                                                                                                                                                                                                              Survival                                        
  ------------------------------------------------------------------------------------------- ------------------------ ------------------ ----------------------------------- ----- ------------------ ------------------ --------------------------------------------- ----------------------------------------------------- ----------------------------------------------- ------
  Miller *et al.*, 2006[@b42-co16-1-27]                                                       Phase [ii]{.smallcaps}   Erlotinib 150 mg   [bac]{.smallcaps}                   102   [nr]{.smallcaps}   [nr]{.smallcaps}   21[a](#tfn6-co16-1-27){ref-type="table-fn"}   3.7 Months                                            17.1                                            
  West *et al.*, 2006[@b43-co16-1-27] (SO126)                                                 Phase [ii]{.smallcaps}   Gefitinib 500 mg   Previously untreated                101   7/93               90/10              17/32/33                                      4 Months                                              13                                              
                                                                                                                                          Previously treated                  35    6/94               86/14              9/36/36                                       3 Months                                              13                                              
  Cadranel *et al.*, 2007[@b44-co16-1-27] and [ifct]{.smallcaps}[@b45-co16-1-27] (IFCT0401)   Phase [ii]{.smallcaps}   Gefitinib 250 mg   Adenocarcinoma, [bac]{.smallcaps}   88    0/100              82/18              13/16/13                                      2.9 Months[b](#tfn7-co16-1-27){ref-type="table-fn"}   13.2[b](#tfn7-co16-1-27){ref-type="table-fn"}   53.4

Response rate.

Shorter progression-free and overall survival were independently associated with non-mucinous as compared with mucinous [bac]{.smallcaps} ([pfs]{.smallcaps}: 11.3 months vs. 2.6 months; *p* = 0.002; [os]{.smallcaps}: not reached vs. 10.7 months; *p* = 0.003).

[ps]{.smallcaps} = performance status; [or]{.smallcaps} = overall response (complete response + partial response); [sd]{.smallcaps} = stable disease; [pd]{.smallcaps} = progressive disease; [pfs]{.smallcaps} = median progression-free survival; [ttp]{.smallcaps} = median time to progression; [nr]{.smallcaps} = not recorded; [ifct]{.smallcaps} = Intergroupe Francophone de Cancerologie Thoracique.

###### 

Randomized trials of first-line epidermal growth factor receptor tyrosine kinase inhibitors ([egfr]{.smallcaps}-[tkis]{.smallcaps}) in combination with platinum-based chemotherapy in patients with non-small-cell lung cancer

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                                                                  Survival       
  ------------------------------------------- ------------------------ ---------------------------- ----- ------- ---------- ---------------------- ------------- -------------- ------
  Giaccone *et al.*, 2004[@b46-co16-1-27]     [intact]{.smallcaps} 1   Cis--gem + placebo           363   30/69   90/10      47.2                   6.0 Months    10.9 Months    44

                                                                       Cis--gem + gefitinib 250     365   27/72   90/10      51.2                   5.8 Months    9.9 Months     41

                                                                       Cis--gem + gefitinib 500     365   33/67   90/10      50.3\                  5.5 Months\   9.9 Months\    43
                                                                                                                             *p*=[ns]{.smallcaps}   *p*=0.763     *p*=0.456      

  Herbst *et al.*, 2004[@b47-co16-1-27]       [intact]{.smallcaps} 2   Carbo--pac + placebo         345   21/78   91/9       28.7                   5.0 Months    9.9 Months     42

                                                                       Carbo--pac + gefitinib 250   345   19/81   90/10      30.4                   5.3 Months    9.8 Months     41

                                                                       Carbo--pac + gefitinib 500   347   18/82   87/13      30.0\                  4.6 Months\   8.7 Months\    37
                                                                                                                             *p*=[ns]{.smallcaps}   *p*=0.056     *p*=0.638      

  Herbst *et al.*, 2005[@b48-co16-1-27]       [tribute]{.smallcaps}    Carbo--pac + placebo         533   18/82   99.8/0.2   19.3                   4.9 Months    10.5 Months    43.8

                                                                       Carbo--pac + erlotinib 150   526   16/84   100/0      21.5\                  5.1 Months\   10.6 Months\   46.9
                                                                                                                             *p*=0.36               *p*=0.36      *p=*0.95       

  Gatzemeier *et al.*, 2007[@b49-co16-1-27]                            Cis--gem + placebo           579   33/67   99/\<1     31.5                   23.7 Weeks    43 Weeks       41

                                                                       Cis--gem + erlotinib 150     580   35/65   100/\<1    29.9\                  24.6 Weeks\   44.1 Weeks     42
                                                                                                                             *p*=0.74               *p*=0.49                     
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

[ps]{.smallcaps} = performance status; [or]{.smallcaps} = overall response (complete response + partial response); [sd]{.smallcaps} = stable disease; [pd]{.smallcaps} = progressive disease; [ttp]{.smallcaps} = median time to progression; [pfs]{.smallcaps} = median progression-free survival; [intact]{.smallcaps} = Iressa [nsclc]{.smallcaps} Trial Assessing Combination Treatment; Cis--gem = gemcitabine 1250 mg/m^2^ intravenously on days 1 and 8, and cisplatin 80 mg/m^2^ intravenously on day 1 of a 21-day cycle; erlotinib 150 = erlotinib 150 mg daily; gefitinib 250 = gefitinib 250 mg daily; gefitinib 500 = gefitinib 500 mg daily; [ns]{.smallcaps} = statistically nonsignificant; Carbo--pac = carboplatin [auc]{.smallcaps} (area under the curve) 6 intravenously on day 1, and paclitaxel 200 mg/m^2^ intravenously on day 1 of a 21-day cycle; [tribute]{.smallcaps} = Tarceva Responses in Conjunction with Paclitaxel and Carboplatin.

###### 

Randomized trials of single-agent epidermal growth factor receptor tyrosine kinase inhibitors ([egfr]{.smallcaps}-[tkis]{.smallcaps}) compared with chemotherapy in chemonaïve patients with non-small-cell lung cancer

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                                                                                                                                                                              Survival                                         
  --------------------------------------------------------------------------------------------------------- ------------------------ -------------------------------------------- ---- ------------------ ------------------ ---------- ------------------------------------- ------------------------------------------------ ------------------
  Crinò *et al.*, 2007[@b50-co16-1-27], [a](#tfn10-co16-1-27){ref-type="table-fn"} ([invite]{.smallcaps})   Phase [ii]{.smallcaps}   Gefitinib                                    97   20/80              76/24              3.1/40     [hr]{.smallcaps}: 1.19                                                                 

                                                                                                                                     Vinorelbine                                  99   26/74              83/16              5.1/48     95% [ci]{.smallcaps}: 0.85 to 1.65\                                                    
                                                                                                                                                                                                                                        *p*=0.310                                                                              

  Riely *et al.*, 2007[@b51-co16-1-27], [b](#tfn11-co16-1-27){ref-type="table-fn"}                          Phase [ii]{.smallcaps}   Erlotinib 150 mg + carboplatin/paclitaxel    87   [nr]{.smallcaps}   [nr]{.smallcaps}   18                                               12                                               

                                                                                                                                     Erlotinib 1500 mg + carboplatin/paclitaxel                                              35                                               16                                               

                                                                                                                                     Carboplatin/paclitaxel + erlotinib 1500 mg                                              24                                               [nr]{.smallcaps} (\>9 )                          

  Lilenbaum *et al.*, 2008[@b52-co16-1-27], [v](#tfn12-co16-1-27){ref-type="table-fn"}                      Phase [ii]{.smallcaps}   Erlotinib                                    52   13/87              0/100              2/37/44    1.9 months                            6.6 [c](#tfn12-co16-1-27){ref-type="table-fn"}   [nr]{.smallcaps}

                                                                                                                                     Carboplatin + paclitaxel                     51   14/86              0/100              12/41/20   3.5 months                            9.1 [c](#tfn12-co16-1-27){ref-type="table-fn"}   
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Gefitinib 250 mg daily compared with vinorelbine 30 mg/m^2^ intravenously on days 1 and 8 in a 21-day cycle.

Erlotinib 150 mg on days 1 and 2, and carboplatin \[area under the curve ([auc]{.smallcaps}) 6\] and paclitaxel (200 mg/m^2^) on day 3; erlotinib 1500 mg on days 1 and 2, and carboplatin ([auc]{.smallcaps} 6) and paclitaxel (200 mg/m^2^) on day 3; or carboplatin ([auc]{.smallcaps} 6) and paclitaxel (200 mg/m^2^) on day 1 and erlotinib 1500 mg on days 2 and3. Patients received up to six 21-day cycles of treatment.

Erlotinib 150 mg daily compared with carboplatin--paclitaxel \[area under the curve ([auc]{.smallcaps}) 6 and 200 mg/m^2^ respectively) for 4 cycles.

[ps]{.smallcaps} = performance status; [or]{.smallcaps} = overall response (complete response + partial response); [sd]{.smallcaps} = stable disease; [pd]{.smallcaps} = progressive disease; [ttp]{.smallcaps} = median time to progression; [pfs]{.smallcaps} = median progression-free survival; [nr]{.smallcaps} = not recorded; [invite]{.smallcaps} = Iressa in [nsclc]{.smallcaps} vs Vinorelbine Investigation in the Elderly; [hr]{.smallcaps} = hazard ratio; [ci]{.smallcaps} = confidence interval.

###### 

Randomized trials of epidermal growth factor receptor tyrosine kinase inhibitors ([egfr]{.smallcaps}-[tkis]{.smallcaps}) as second- or third line therapy following progression of platinum-based chemotherapy

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                                                                 Treatment line                                                                                                                                                  Survival                                 
  ------------------------------------------------------------------------------------------------------------- ------------------------- --------------- ------ ---------------- ------- ----------------------- ------------------ ------------------ ------------------------------------------------- ---------------------- ------------------ ---------- ---------- ---------
  Fukuoka *et al.*, 2003 [@b54-co16-1-27], [a](#tfn14-co16-1-27){ref-type="table-fn"} ([ideal]{.smallcaps} 1)   Phase [ii]{.smallcaps}    Gefitinib 250   104    66               44      100/[nr]{.smallcaps}    [nr]{.smallcaps}   22/88              88/12                                             18.4/36/41             2.7                7.6        35         \>0.05

                                                                                                                                          Gefitinib 500   106    67               33      100                                        17/83              87/13                                             19.0/32/42\            2.8                8.0        29         
                                                                                                                                                                                                                                                                                                          *p*=[ns]{.smallcaps}                                            

  Kris *et al.*, 2003 [@b55-co16-1-27], [b](#tfn15-co16-1-27){ref-type="table-fn"} ([ideal]{.smallcaps} 2)      Phase [ii]{.smallcaps}    Gefitinib 250   102    0                40/58   100/[nr]{.smallcaps}    [nr]{.smallcaps}   15/85              81/19                                             12/--/--               [nr]{.smallcaps}   7.0        27         0.54

                                                                                                                                          Gefitinib 500   114    0                42/58   100                                        8/92               79/20                                             9/--/--\                                  6.0\       24\        
                                                                                                                                                                                                                                                                                                          *p*=0.51                                  *p*=0.40   *p*=0.54   

  Shepherd *et al.*, 2005 [@b56-co16-1-27], [c](#tfn16-co16-1-27){ref-type="table-fn"} ([br]{.smallcaps}.21)    Phase [iii]{.smallcaps}   Erlotinib 150   488    51               49      92/[nr]{.smallcaps}     28                 [nr]{.smallcaps}   66/34[d](#tfn17-co16-1-27){ref-type="table-fn"}   8.9/36/45              2.2                6.7        31         \<0.001

                                                                                                                                          Placebo         243    50               50      91.8/[nr]{.smallcaps}   28                                    68/32[d](#tfn17-co16-1-27){ref-type="table-fn"}   \<1/27/57\             1.8                4.7        21         
                                                                                                                                                                                                                                                                                                          *p\<*0.001                                                      

  Thatcher *et al.*, 2005 [@b57-co16-1-27], [e](#tfn18-co16-1-27){ref-type="table-fn"} ([isel]{.smallcaps})     Phase [iii]{.smallcaps}   Gefitinib 250   1129   49               50/1    96/27                   38                 44/47              65/29                                             8/32/37                3.0                5.6        27         0.087

                                                                                                                                          Placebo         563    49               50/1    96/28                   40                 39/50              68/26                                             1/31/48\               2.6                5.1        21         
                                                                                                                                                                                                                                                                                                          *p*\<0.0001                                                     
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Gefitinib 250 mg daily vs. gefitinib 500 mg daily.

Gefitinib 250 mg daily vs. gefitinib 500 mg daily.

Erlotinib 150 mg daily vs. placebo.

Includes patients with performance status 3 (8.6% in each arm).

Gefitinib 250 mg daily vs. placebo.

Pts = patients; [pd]{.smallcaps} = progressive disease; [ps]{.smallcaps} = performance status; [or]{.smallcaps} = overall response (complete response + partial response); [sd]{.smallcaps} = stable disease; [ttp]{.smallcaps} = median time to progression; [pfs]{.smallcaps} = median progression-free survival; [os]{.smallcaps} = overall survival; [nr]{.smallcaps} = not recorded; [isel]{.smallcaps} = Iressa Survival Evaluation in Lung Cancer; [ideal]{.smallcaps} = Iressa Dose Evaluation in Advanced Lung Cancer; [ns]{.smallcaps} = statistically nonsignificant.

###### 

Randomized trials of epidermal growth factor receptor tyrosine kinase inhibitors ([egfr]{.smallcaps}-[tki]{.smallcaps}s) compared with chemotherapy following progression after platinum-based chemotherapy

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                                                                                       Treatment line                                                                                     Survival                                                                                                   
  ---------------------------------------------------------------------------------------------------------------- ------------------------- ---------------------------- ------------ ---------------- -------- -------- ------------------ ------------------ ------------ ------------ ----------------------------------------------------- ---------------------------------------------------- ------------------------------------------------------------
  Cufer *et al.,* 2006 [@b59-co16-1-27], [a](#tfn20-co16-1-27){ref-type="table-fn"} ([sign]{.smallcaps})           Phase [ii]{.smallcaps}    Gefitinib 250                68           97               ---      91/0     [nr]{.smallcaps}   [nr]{.smallcaps}   63/37        13.2         3.0 months                                            7.5 months                                           [nr]{.smallcaps}[b](#tfn21-co16-1-27){ref-type="table-fn"}

                                                                                                                                             Docetaxel 75                 73           99               ---      96/0                                           71/29        13.7         3.4 months\                                           7.1 months                                           
                                                                                                                                                                                                                                                                                          *p*=0.88                                                                                                   

  Natale *et al.*, 2006 [@b60-co16-1-27], [c](#tfn22-co16-1-27){ref-type="table-fn"}                               Phase [ii]{.smallcaps}    ZD6474                       83           100                       100/--   100                [nr]{.smallcaps}   100/--       --/45/--     11 weeks                                              6.1                                                  [nr]{.smallcaps}

                                                                                                                                             Gefitinib 250                85           100              ---      100/--   100                                                --/34/--     8.1 weeks\                                            7.4                                                  
                                                                                                                                                                                                                                                                                          *p*=0.025                                                                                                  

  Chen *et al.*, 2007 [@b61-co16-1-27], [d](#tfn23-co16-1-27){ref-type="table-fn"}                                 Phase [ii]{.smallcaps}    Gefitinib 250                27           ---              100      100/--   [nr]{.smallcaps}   [nr]{.smallcaps}   59/37        55.6         7.1 months                                            13.3 months                                          51.3

                                                                                                                                             Gefitinib 250\               21           ---              100      100/--                                         76/24        52.4         12.8 months\                                          23.4 months                                          75.3
                                                                                                                                             + vinorelbine 15                                                                                                                             *p*=0.133[e](#tfn24-co16-1-27){ref-type="table-fn"}                                                        

  Douillard *et al.*, 2007 [@b62-co16-1-27], [f](#tfn25-co16-1-27){ref-type="table-fn"} ([interest]{.smallcaps})   Phase [iii]{.smallcaps}   Gefitinib 250                733          100              100/--   26       14/86              88/12              9.1          2.2 months   7.6 months                                            32                                                   

                                                                                                                                             Docetaxel 75                 733          100              100/--   25       13/87              88/12              7.6\         2.7 months   8.0 months                                            34                                                   
                                                                                                                                                                                                                                                                *p*=0.3257                                                                                                                           

  Herbst *et al.*, 2007 [@b63-co16-1-27], [g](#tfn26-co16-1-27){ref-type="table-fn"}                               Phase [ii]{.smallcaps}    Chemotherapy + placebo       41           100              ---      100/--   36.6               [nr]{.smallcaps}   98/2         12.2/27      3.0 months                                            8.6 months                                           33.1

                                                                                                                                             Chemotherapy + bevacizumab   40           100              ---      100/--   17.5                                  100/0        12.5/40      4.8 months                                            12.6 months                                          53.8

                                                                                                                                             Bevacizumab + erlotinib      39                                              33.3                                  100/0        17.9/33      4.4 months                                            13.7 months                                          57.4

  Lynch *et al.*, 2007[@b64-co16-1-27], [h](#tfn27-co16-1-27){ref-type="table-fn"}                                 Phase [ii]{.smallcaps}    Erlotinib 150                50 (total)   100              ---      100      100                [nr]{.smallcaps}   100/--       17/--/--     2.7 months                                            [nr]{.smallcaps}                                     [nr]{.smallcaps}

                                                                                                                                             Erlotinib 150 + bortezomi                                                                                                       8/--/--      1.4 months                                                                                                 

  Niho *et al.*, 2007 [@b65-co16-1-27], [@b66-co16-1-27], [i](#tfn27-co16-1-27){ref-type="table-fn"}               Phase [iii]{.smallcaps}   Gefitinib 250                244          87               13       100/--   17                 19/81              96/4         22.5/12/66   2.0 months                                            11.5 months                                          48

                                                                                                                                             Docetaxel 60                 245          82               17       100/--   15                 20/79              96/4         12.8/21/66   2.0 months                                            14.0 months\                                         54
                                                                                                                                                                                                                                                                                                                                                *p*=0.33[e](#tfn24-co16-1-27){ref-type="table-fn"}   
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Gefitinib 250 mg daily vs. docetaxel 75 mg/m^2^ intravenously every 3 weeks.

6-Month survival rates were 65.6% with gefitinib and 56.1% with docetaxel.

ZD6474 300 mg daily vs. gefitinib 250 mg daily.

Gefitinib 250 mg daily vs. vinorelbine 15 mg/m^2^ intravenously on day 1, and gefitinib 250 mg daily on days 2--14 every 2 weeks.

Overall survival.

Gefitinib 250 mg daily vs. docetaxel 75 mg/m^2^ intravenously every 3 weeks.

Chemotherapy (docetaxel or pemetrexed); bevacizumab 15 mg daily intravenously on day 1 of each 3-week cycle (± 5 days); erlotinib 150 mg daily for up to 52 weeks; docetaxel over 60 minutes (± 10 minutes) 75 mg/m^2^ on day 1 of a 3-week cycle (± 5 days); pemetrexed over 10 minutes (± 5 minutes) 500 mg/m^2^ on day 1 of a 3-week cycle. ^h^ Erlotinib150 mg daily vs. erlotinib 150 mg daily + bortezomib 1.6 mg/m^2^ intravenously on days 1 and 8 of a 21-day cycle. The study was halted as required at the planned interim analysis because of insufficient clinical activity in the erlotinib + bortezomib arm.

Gefitinib 250 mg daily vs. docetaxel 60 mg/m^2^ intravenously every 3 weeks.

Pts = Patients; [pd]{.smallcaps} = progressive disease; [ps]{.smallcaps} = performance status; [or]{.smallcaps} = overall response (complete response + partial response); [sd]{.smallcaps} = stable disease; [ttp]{.smallcaps} = median time to progression; [pfs]{.smallcaps} = median progression-free survival; [sign]{.smallcaps} = Second-Line Indication of Gefitinib in [nsclc; nr]{.smallcaps} = not recorded; [interest]{.smallcaps} = Iressa non-small-cell lung cancer trial evaluating response and survival against Taxotere.

###### 

Trials of clinical characteristics that predict response from therapy with epidermal growth factor receptor tyrosine kinase inhibitors ([egfr]{.smallcaps}-[tki]{.smallcaps}s)

  Reference                                    Study                   Patients (*n*)   Treatment                                           Adenocarcinoma   Never smokers    Female sex       Asian ethnicity
  -------------------------------------------- ----------------------- ---------------- --------------------------------------------------- ---------------- ---------------- ---------------- -----------------
  Kris *et al.*, 2003 [@b55-co16-1-27]         [ideal]{.smallcaps} 2   216              Gefitinib 250 mg daily vs. gefitinib 500 mg daily   13% vs. 4%                        19% vs. 3%       
  Shepherd *et al.*, 2005 [@b56-co16-1-27]     [br]{.smallcaps}.21     731              Erlotinib 150 mg daily vs. placebo                  *n*=427          *n*=427          *n*=427          *n*=427
  Clark *et al.*, 2006 [@b71-co16-1-27], ^a^                                                                                                13.9% vs. 4.1%   24.7% vs. 3.9%   14.4% vs. 6%     18.9% vs. 7.5%
  Florescu *et al.*, 2006 [@b72-co16-1-27]                                                                                                  *p\<*0.001       *p\<*0.001       *p=*0.006        *p*=0.002
  Tsao *et al.*, 2006 [@b73-co16-1-27]                                                                                                                                                         
  Thatcher *et al.*, 2005 [@b57-co16-1-27]     [isel]{.smallcaps}      1439             Gefitinib 250 mg daily vs. placebo                  *n*=1439         *n*=1439         *n*=1439         *n*=1439
                                                                                                                                            11.9% vs. 4.8%   18.1% vs. 5.3%   14.7% vs. 5.1%   12.4% vs. 7.5%

[isel]{.smallcaps} = Iressa Survival Evaluation in Lung Cancer; [ideal]{.smallcaps} = Iressa Dose Evaluation in Advanced Lung Cancer.

###### 

Trials of clinical characteristics that predict survival from therapy with epidermal growth factor receptor tyrosine kinase inhibitors ([egfr]{.smallcaps}-[tki]{.smallcaps}s)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                                                                            Design                    Patients (*n*)   Treatment                                                             Adenocarcinoma (HR)   Never smokers (HR)                      Female sex (HR)   Asian ethnicity (HR)
  ------------------------------------------------------------------------------------ ------------------------- ---------------- --------------------------------------------------------------------- --------------------- --------------------------------------- ----------------- ----------------------
  Gatzemeier *et al.*, 2005 [@b74-co16-1-27],[@b75-co16-1-27] ([talent]{.smallcaps})   Phase [iii]{.smallcaps}   1159             Erlotinib 150 mg daily vs. chemotherapy plus erlotinib 150 mg daily                         Never-smoker [hr]{.smallcaps}: 0.39\                      
                                                                                                                                                                                                                              *p=*0.25\                                                 
                                                                                                                                                                                                                              Former-smoker [hr]{.smallcaps}: 1.05\                     
                                                                                                                                                                                                                              *p*=0.86                                                  

  Thatcher *et al.*, 2005 [@b57-co16-1-27] ([isel]{.smallcaps})                                                  1439             Gefitinib 250 mg daily vs. placebo                                    0.84                  0.69 vs. 0.92                                             0.66 vs. 0.92

  Chang *et al.*, 2006 [@b76-co16-1-27] ([isel]{.smallcaps})                                                     342              Gefitinib 250 mg daily vs. placebo (subset of Asian population)       0.66 vs. 0.86         0.37 vs. 0.85                           0.46 vs. 0.80     All-Asian population

  Clark *et al.*, 2006 [@b71-co16-1-27],[@b77-co16-1-27],^a,b^                                                   731              Erlotinib 150 mg daily vs. placebo                                    0.7 vs. 0.8           0.4 vs. 0.9                             0.8 vs. 0.8       0.6 vs. 0.8

  Florescu *et al.*, 2006 [@b72-co16-1-27]                                                                                                                                                                                                                                              

  Tsao *et al.*, 2006 [@b73-co16-1-27]                                                                                                                                                                                                                                                  

  Shepherd *et al.*, 2007 [@b78-co16-1-27] ([br]{.smallcaps}.21)                                                                                                                                                                                                                        

  Douillard *et al.*, 2007 [@b79-co16-1-27] ([interest]{.smallcaps})                   Phase [iii]{.smallcaps}   1466             Gefitinib 250 mg daily vs. docetaxel                                  *p\>*0.05             *p\>*0.05                               *p\>*0.05         *p\>*0.05
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

[hr]{.smallcaps} = hazard ratio; [isel]{.smallcaps} = Iressa Survival Evaluation in Lung Cancer; [talent]{.smallcaps} = Tarceva Lung Cancer Investigation Trial; [interest]{.smallcaps} = IIressa non-small-cell lung cancer trial evaluating response and survival against Taxotere.

###### 

Trials of molecular characteristics that predict response from therapy with epidermal growth factor receptor tyrosine kinase inhibitors ([egfr-tkis]{.smallcaps})

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                                                                                                                           Design                                     Patients (n)   Treatment                                                 Protein expression ([ihc]{.smallcaps})              EGFR High gene copy (amplification ± high polysomy)   Mutations                                             KRAS Mutations
  ----------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------ -------------- --------------------------------------------------------- --------------------------------------------------- ----------------------------------------------------- ----------------------------------------------------- ----------------------
  Bell *et al.*, 2005 [@b80-co16-1-27] ([ideal]{.smallcaps} 1/[ideal]{.smallcaps} 2, [intact]{.smallcaps} 1/[intact]{.smallcaps} 2)   Phase [ii]{.smallcaps}/[iii]{.smallcaps}   425            Gefitinib monotherapy (250 mg vs. 500 mg daily)                                                               *n*=90\                                               *n*=79\                                               
                                                                                                                                                                                                                                                                                                              [qpcr]{.smallcaps}^+^ 29% vs. 15%\                    46% vs.10%\                                           
                                                                                                                                                                                                                                                                                                              *p*=0.319                                             *p*=0.005                                             

                                                                                                                                                                                 2130           Chemotherapy + gefitinib (250 mg daily or 500 mg daily)                                                       *n*=235\                                              *n*=170\                                              
                                                                                                                                                                                                                                                                                                              [qpcr]{.smallcaps}^+^ 56% vs. 53%\                    mut^+^ 72% vs. 55%\                                   
                                                                                                                                                                                                                                                                                                              *p=*[ns]{.smallcaps}                                  *p=*[ns]{.smallcaps}                                  

  Eberhard *et al.*, 2005 [@b82-co16-1-27]                                                                                            Phase [iii]{.smallcaps}                    1079           Erlotinib 150 mg daily                                                                                        *n*=245[a](#tfn31-co16-1-27){ref-type="table-fn"}     *n*=228                                               *n*=264

  Gatzemeier *et al.*, 2005[@b74-co16-1-27]^,^[@b75-co16-1-27] ([talent]{.smallcaps})                                                 Phase [iii]{.smallcaps}                    500            Chemotherapy + erlotinib 150 mg daily                     *n*=375\                                                                                                  *n* =293\                                             *n*=293\
                                                                                                                                                                                                                                                          No difference                                                                                             *p*=[ns]{.smallcaps}                                  *p*=[ns]{.smallcaps}

  Hirsch *et al.*, 2006 [@b83-co16-1-27] ([isel]{.smallcaps})                                                                         Phase [iii]{.smallcaps}                    1692           Gefitinib 250 mg daily + carboplatin/paclitaxel           *n*=303\                                            *n*=317\                                              *n*=215\                                              *n*=93\
                                                                                                                                                                                                                                                          [ihc]{.smallcaps}^+^ 8.2% vs. 1.5%                  [fish]{.smallcaps}^+^ 16.4% vs. 3.2%                  mut^+^ 37.5% vs. 2.6%                                 ras^+^ 0% vs. 8%

  Hirsch *et al.*, 2007 [@b84-co16-1-27] ([tribute]{.smallcaps})                                                                                                                                                                                                                                              [fish]{.smallcaps}^+^ 12% vs 22%\                     mut^+^ 53% vs. 18%\                                   ras^+^ 8% vs. 26%\
                                                                                                                                                                                                                                                                                                              *p*=[ns]{.smallcaps}                                  *p\<*0.01                                             *p*=0.16

  Zhu *et al.*, 2008 [@b85-co16-1-27] ([br]{.smallcaps}.21)                                                                                                                      731            Erlotinib 150 mg daily                                    *n*=325\                                            *n*=159\                                              *n*=204\                                              *n*=206\
                                                                                                                                                                                                                                                          11% vs. 4%\                                         [fish]{.smallcaps}^+^ 21% vs. 5%\                     mut^+^ 27% vs. 7%\                                    ras^+^ 5% vs. 10%\
                                                                                                                                                                                                                                                          *p*=0.1[b](#tfn32-co16-1-27){ref-type="table-fn"}   *p*=0.02[b](#tfn32-co16-1-27){ref-type="table-fn"}    *p*=0.035[b](#tfn32-co16-1-27){ref-type="table-fn"}   *p*=0.69
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Decrease in response.

Univariate analysis.

[ihc]{.smallcaps} = immunohistochemistry; [ideal]{.smallcaps} = Iressa Dose Evaluation in Advanced Lung Cancer; [intact]{.smallcaps} = Iressa [nsclc]{.smallcaps} Trial Assessing Combination Treatment; [qpcr]{.smallcaps} = amplification determined by an increase in gene copy by a factor of 4 or more, as assessed by quantitative polymerase chain reaction; mut^+^ = mutation present; [ns]{.smallcaps} = statistically nonsignificant; [fish]{.smallcaps} = fluorescence *in situ* hybridization showing amplification or high polysomy; [tribute]{.smallcaps} = Tarceva Responses in Conjunction with Paclitaxel and Carboplatin; [talent]{.smallcaps} = Tarceva Lung Cancer Investigation Trial; [isel]{.smallcaps} = Iressa Survival Evaluation in Lung Cancer.

###### 

Trials of molecular characteristics that predict survival for therapy with epidermal growth factor receptor tyrosine kinase inhibitors ([egfr-tkis]{.smallcaps})

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                                                                                                                                                Design                                                                                    Patients (n)   Treatment                                                                              Protein expression ([ihc]{.smallcaps})         EGFR High gene copy (amplification ± high polysomy)   Mutations                                                                       KRAS Mutations
  -------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------- -------------- -------------------------------------------------------------------------------------- ---------------------------------------------- ----------------------------------------------------- ------------------------------------------------------------------------------- --------------------------------------------------------------
  Bell 2005 [@b80-co16-1-27], [a](#tfn34-co16-1-27){ref-type="table-fn"} ([ideal]{.smallcaps} and [intact]{.smallcaps})                                    [ideal]{.smallcaps} 1/[ideal]{.smallcaps} 2, phase [ii]{.smallcaps}/[iii]{.smallcaps}     425            Gefitinib monotherapy (250 mg and 500 mg daily)                                                                                       *n*=90\                                               *n*=119[b](#tfn36-co16-1-27){ref-type="table-fn"}\                              
                                                                                                                                                                                                                                                                                                                                                                                                          No difference in survival\                            [ttp]{.smallcaps}: 116 days vs. 57 days                                         
                                                                                                                                                                                                                                                                                                                                                                                                          No difference in survival                                                                                                             

                                                                                                                                                           [intact]{.smallcaps} 1/[intact]{.smallcaps} 2, phase [ii]{.smallcaps}/[iii]{.smallcaps}   2130           Chemotherapy vs. Chemotherapy + gefitinib (250 mg or 500 mg daily)                                                                    *n*=453\                                              *n*=312\                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                          [fish]{.smallcaps}^+^[hr]{.smallcaps}: 2.03\          mut^+^[hr]{.smallcaps}: 1.77\                                                   
                                                                                                                                                                                                                                                                                                                                                                                                          95% [ci]{.smallcaps}: 0.67 to 6.13\                   95% [ci]{.smallcaps}: 0.5 to 6.2\                                               
                                                                                                                                                                                                                                                                                                                                                                                                          [fish]{.smallcaps}^−^[hr]{.smallcaps}: 1.01\          mut^−^[hr]{.smallcaps}: 0.91\                                                   
                                                                                                                                                                                                                                                                                                                                                                                                          95% [ci]{.smallcaps}: 0.79 to 1.29\                   95% [ci]{.smallcaps}: 0.67 to 1.23\                                             
                                                                                                                                                                                                                                                                                                                                                                                                          *p=*[ns]{.smallcaps}                                  *p=*[ns]{.smallcaps}                                                            

  Eberhard *et al.*, 2005 [@b82-co16-1-27], [c](#tfn37-co16-1-27){ref-type="table-fn"}\                                                                    Phase [iii]{.smallcaps}                                                                   1079           Erlotinib 150 mg daily + carboplatin/paclitaxel vs. placebo + carboplatin/paclitaxel                                                  *n*=245\                                              *n*=274\                                                                        *n*=274\
  Hirsch *et al.*, [@b84-co16-1-27], [d](#tfn38-co16-1-27){ref-type="table-fn"} 2007 ([tribute]{.smallcaps})                                                                                                                                                                                                                                                                                              [fish]{.smallcaps}\                                   mut^+^[ttp]{.smallcaps}: 12.5 months vs. 6.6 months\                            ras^+^[hr]{.smallcaps}: 2.1\
                                                                                                                                                                                                                                                                                                                                                                                                          No difference in survival\                            *p*=0.092\                                                                      95% [ci]{.smallcaps}: 1.1 vs. 3.8\
                                                                                                                                                                                                                                                                                                                                                                                                          [ttp hr]{.smallcaps}: 0.59\                           No difference in [os]{.smallcaps}\                                              4.4 months vs. 13.5 months\
                                                                                                                                                                                                                                                                                                                                                                                                          95% [ci]{.smallcaps}: 0.35 to 0.99\                   *p*=0.96                                                                        *p*=0.019 ras^−^ 12.1 months vs. 11.3 months
                                                                                                                                                                                                                                                                                                                                                                                                          [os]{.smallcaps} similar in both treatment arms                                                                                       

  Gatzemeier *et al.*, 2005[@b74-co16-1-27],[@b75-co16-1-27] ([talent]{.smallcaps})                                                                        Phase [iii]{.smallcaps}                                                                   500            Erlotinib 150 mg daily vs. chemotherapy + erlotinib 150 mg daily                       *n*=375\                                                                                             [os]{.smallcaps}: *p*=0.40 (erlotinib), *p*=0.65 (placebo)\                     [os]{.smallcaps}: *p*=0.51 (erlotinib)\
                                                                                                                                                                                                                                                                                                                                                           No difference                                                                                        *n*=293\                                                                        *n*=293\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                [pfs]{.smallcaps}: *p*=0.18 (erlotinib), *p*=0.74 (placebo)\                    [pfs]{.smallcaps}: *p*=0.77 (erlotinib), *p*=0.22 (placebo)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                *n*=293                                                                         *n*=293

  Clark *et al.*, 2006 [@b71-co16-1-27],[@b77-co16-1-27],[e](#tfn39-co16-1-27){ref-type="table-fn"}\                                                                                                                                                 731            Erlotinib 150 mg daily vs. placebo                                                     *n*=325\                                       *n*=159\                                              *n*=204\                                                                        *n*=206\
  Tsao *et al.*, 2006 [@b73-co16-1-27], [e](#tfn39-co16-1-27){ref-type="table-fn"}\                                                                                                                                                                                                                                                                        [ihc]{.smallcaps}^+^[hr]{.smallcaps}: 0.68\    [fish]{.smallcaps}^+^[hr]{.smallcaps}: 0.43\          mut^+^[hr]{.smallcaps}: 0.55\                                                   ras^+^[hr]{.smallcaps}: 1.67\
  Zhu *et al.*, 2008[@b85-co16-1-27], [e](#tfn39-co16-1-27){ref-type="table-fn"} ([br]{.smallcaps}.21)                                                                                                                                                                                                                                                     95% [ci]{.smallcaps}: 0.49 to 0.95\            95% [ci]{.smallcaps}: 0.23 to 0.78\                   95% [ci]{.smallcaps}: 0.25 to 1.19[e](#tfn39-co16-1-27){ref-type="table-fn"}\   95% [ci]{.smallcaps}: 0.62 to 4.50\
                                                                                                                                                                                                                                                                                                                                                           [ihc]{.smallcaps}^−^[hr]{.smallcaps}: 0.93\    [fish]{.smallcaps}^−^[hr]{.smallcaps}: 0.80\          mut^−^[hr]{.smallcaps}: 0.74\                                                   ras^−^[hr]{.smallcaps}: 0.69\
                                                                                                                                                                                                                                                                                                                                                           95% [ci]{.smallcaps}: 0.63 to 1.36\            95% [ci]{.smallcaps}: 0.49 to 1.29\                   95% [ci]{.smallcaps}: 0.52 to 1.05\                                             95% [ci]{.smallcaps}: 0.49 to 0.97\
                                                                                                                                                                                                                                                                                                                                                           *p*=0.1                                        Interaction *p*=0.12                                  *p*=0.47                                                                        *p*=0.09

  Hirsch *et al.*, 2006[@b83-co16-1-27] ([isel]{.smallcaps})                                                                                               Phase [iii]{.smallcaps}                                                                   1692           Gefitinib 250 mg daily and placebo                                                     *n=*379\                                       *n*=370\                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                           [ihc]{.smallcaps}^+^[hr]{.smallcaps}: 0.77\    [fish]{.smallcaps}^+^[hr]{.smallcaps}: 0.61\                                                                                          
                                                                                                                                                                                                                                                                                                                                                           95% [ci]{.smallcaps}: 0.56 to 1.08\            95% [ci]{.smallcaps}: 0.36 to 1.04\                                                                                                   
                                                                                                                                                                                                                                                                                                                                                           [ihc]{.smallcaps}^−^[hr]{.smallcaps}: 1.57\    [fish]{.smallcaps}^−^[hr]{.smallcaps}: 1.16\                                                                                          
                                                                                                                                                                                                                                                                                                                                                           95% [ci]{.smallcaps}: 0.86 to 2.87\            95% [ci]{.smallcaps}: 0.81 to 1.64\                                                                                                   
                                                                                                                                                                                                                                                                                                                                                           Interaction *p=*0.049                          Interaction *p=*0.045                                                                                                                 

  Douillard *et al.*, 2007[@b79-co16-1-27] ([interest]{.smallcaps})                                                                                        Phase [iii]{.smallcaps}                                                                   1466           Gefitinib 250 mg daily vs. docetaxel                                                   *p*=[ns]{.smallcaps}                           *p*=[ns]{.smallcaps}                                  *p*=[ns]{.smallcaps}                                                            *p*=[ns]{.smallcaps}

  Garassino *et al.*, 2007[@b86-co16-1-27] (Pooled subset from [isel]{.smallcaps}, [intact]{.smallcaps}, [tribute]{.smallcaps}, and [br]{.smallcaps}.21)                                                                                             1350           Gefitinib 250 mg daily vs. placebo\                                                    *n*=325\                                       *n*=578\                                              *n*=447\                                                                        
                                                                                                                                                                                                                                                                    Erlotinib 150 mg daily vs. placebo                                                     [egfr]{.smallcaps}^+^[hr]{.smallcaps}: 0.72\   [fish]{.smallcaps}^+^[hr]{.smallcaps}: 0.63\          mut^+^[hr]{.smallcaps}: 0.92\                                                   
                                                                                                                                                                                                                                                                                                                                                           [egfr]{.smallcaps}^−^[hr]{.smallcaps}: 1.08\   [fish]{.smallcaps}^−^[hr]{.smallcaps}: 1.03\          mut^−^[hr]{.smallcaps}: 0.85\                                                   
                                                                                                                                                                                                                                                                                                                                                           Interaction *p*=0.048                          Interaction *p*=0.022                                 Interaction *p*=0.796                                                           
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

[intact]{.smallcaps} 1: Chemotherapy (gemcitabine + cisplatin, *n*=363) + placebo vs. chemotherapy + gefitinib 250 mg daily (*n*=365) vs. chemotherapy + gefitinib 500 mg daily (*n*=365).

Gemcitabine 1250 mg/m^2^ intravenously on days 1 and 8; cisplatin 80 mg/m^2^ intravenously after gemcitabine on day 1 of a 21-day cycle; [intact]{.smallcaps} 2: Chemotherapy (paclitaxel + carboplatin) + placebo (*n*=345) vs. chemotherapy + gefitinib 250 mg daily vs. chemotherapy (*n*=345) + gefitinib 500 mg daily (*n*=347). Paclitaxel 225 mg/m^2^ intravenously on day 1; carboplatin \[area under the curve ([auc]{.smallcaps}) 6\] on day 1 of a 21-day cycle; [ideal]{.smallcaps} 1: gefitinib 250 mg daily (*n*=104) vs. gefitinib 500 mg daily (*n*=106); [ideal]{.smallcaps} 2, gefitinib 250 mg daily (*n*=102) vs. gefitinib 500 mg daily (*n*=114).

Median time to progression: [egfr]{.smallcaps} mut^+^ \> [egfr]{.smallcaps} mut^−^. No effect on overall survival.

Univariate analysis.

[tribute]{.smallcaps}: Chemotherapy (carboplatin + paclitaxel) + placebo vs. erlotinib 150 mg daily. Carboplatin \[area under the curve ([auc]{.smallcaps}) 6\] intravenously on day 1; paclitaxel 200 mg/m^2^ intravenously on day 1 of a 21-day cycle.

[tribute]{.smallcaps}: Chemotherapy (carboplatin + paclitaxel) + placebo vs. erlotinib 150 mg daily. Carboplatin \[area under the curve ([auc]{.smallcaps}) 6\] intravenously on day 1; paclitaxel 200 mg/m^2^ intravenously on day 1 of a 21-day cycle.

[ihc]{.smallcaps} = immunohistochemistry; [ideal]{.smallcaps} = Iressa Dose Evaluation in Advanced Lung Cancer; [intact]{.smallcaps} = Iressa [nsclc]{.smallcaps} Trial Assessing Combination Treatment; [ttp]{.smallcaps} = time to progression; [fish]{.smallcaps} = fluorescence *in situ* hybridization showing amplification or high polysomy; [hr]{.smallcaps} = hazard ratio; mut[+]{.smallcaps} = mutation present; [ci]{.smallcaps} = confidence interval; [ns]{.smallcaps} = statistically nonsignificant; [tribute]{.smallcaps} = Tarceva Responses in conjunction with Paclitaxel and Carboplatin; [interest]{.smallcaps} = Iressa non-small-cell lung cancer trial evaluating response and survival against Taxotere; [isel]{.smallcaps} = Iressa Survival Evaluation in Lung Cancer; [talent]{.smallcaps} = Tarceva Lung Cancer Investigation Trial; [os]{.smallcaps} = overall survival; [pfs]{.smallcaps} = median progression-free survival.
